WO2020234884A1 - Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth - Google Patents
Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth Download PDFInfo
- Publication number
- WO2020234884A1 WO2020234884A1 PCT/IL2020/050560 IL2020050560W WO2020234884A1 WO 2020234884 A1 WO2020234884 A1 WO 2020234884A1 IL 2020050560 W IL2020050560 W IL 2020050560W WO 2020234884 A1 WO2020234884 A1 WO 2020234884A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- mbsfl
- bsfl
- mcfas
- acid
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 36
- 241000709785 Hermetia illucens Species 0.000 title claims abstract description 18
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 title claims description 153
- 230000032770 biofilm formation Effects 0.000 title description 34
- 238000011282 treatment Methods 0.000 title description 8
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 41
- 239000000194 fatty acid Substances 0.000 claims abstract description 41
- 229930195729 fatty acid Natural products 0.000 claims abstract description 41
- 238000009472 formulation Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 33
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 31
- -1 fatty acid salts Chemical class 0.000 claims abstract description 29
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 29
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000011161 development Methods 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 238000007127 saponification reaction Methods 0.000 claims abstract description 15
- 230000000699 topical effect Effects 0.000 claims abstract description 12
- 230000007062 hydrolysis Effects 0.000 claims abstract description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 10
- 230000002500 effect on skin Effects 0.000 claims abstract description 9
- 238000012545 processing Methods 0.000 claims abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 239000005639 Lauric acid Substances 0.000 claims description 74
- 230000000845 anti-microbial effect Effects 0.000 claims description 30
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 150000004665 fatty acids Chemical class 0.000 claims description 17
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 17
- 230000018109 developmental process Effects 0.000 claims description 15
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 13
- 230000002538 fungal effect Effects 0.000 claims description 13
- 230000003214 anti-biofilm Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 10
- 229940070765 laurate Drugs 0.000 claims description 10
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 9
- 206010017533 Fungal infection Diseases 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 8
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 208000008960 Diabetic foot Diseases 0.000 claims description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
- 208000031888 Mycoses Diseases 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 6
- 235000021360 Myristic acid Nutrition 0.000 claims description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 6
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- 229960004488 linolenic acid Drugs 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 208000002474 Tinea Diseases 0.000 claims description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
- 201000004647 tinea pedis Diseases 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 4
- 230000036576 dermal application Effects 0.000 claims description 4
- 230000007803 itching Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 206010012504 Dermatophytosis Diseases 0.000 claims description 3
- 241001460074 Microsporum distortum Species 0.000 claims description 3
- 208000010195 Onychomycosis Diseases 0.000 claims description 3
- 208000007027 Oral Candidiasis Diseases 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 201000005882 tinea unguium Diseases 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000003014 Bites and Stings Diseases 0.000 claims description 2
- 206010006326 Breath odour Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010012444 Dermatitis diaper Diseases 0.000 claims description 2
- 208000003105 Diaper Rash Diseases 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 206010048222 Xerosis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003679 aging effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
- 241000233866 Fungi Species 0.000 abstract description 12
- 241000700605 Viruses Species 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000003921 oil Substances 0.000 description 199
- 235000019198 oils Nutrition 0.000 description 199
- 230000000694 effects Effects 0.000 description 31
- 241000191967 Staphylococcus aureus Species 0.000 description 29
- 229960002152 chlorhexidine acetate Drugs 0.000 description 14
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 14
- 241000222122 Candida albicans Species 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 229940095731 candida albicans Drugs 0.000 description 12
- 241000223229 Trichophyton rubrum Species 0.000 description 11
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 9
- 241000194019 Streptococcus mutans Species 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 241000222126 [Candida] glabrata Species 0.000 description 8
- 230000000843 anti-fungal effect Effects 0.000 description 8
- 208000032343 candida glabrata infection Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 235000021313 oleic acid Nutrition 0.000 description 7
- 239000012449 sabouraud dextrose agar Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940121375 antifungal agent Drugs 0.000 description 6
- 150000002759 monoacylglycerols Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 5
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 5
- 241001480036 Epidermophyton floccosum Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 229960002206 bifonazole Drugs 0.000 description 5
- 150000001982 diacylglycerols Chemical class 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 5
- 229940082004 sodium laurate Drugs 0.000 description 5
- 229960002722 terbinafine Drugs 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000893980 Microsporum canis Species 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940089474 lamisil Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 241000186779 Listeria monocytogenes Species 0.000 description 3
- 201000010618 Tinea cruris Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003346 palm kernel oil Substances 0.000 description 3
- 235000019865 palm kernel oil Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000001974 tryptic soy broth Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102100028216 DNA polymerase zeta catalytic subunit Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000308760 Helichrysum petiolatum Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000579381 Homo sapiens DNA polymerase zeta catalytic subunit Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 208000005035 cutaneous candidiasis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 208000013431 dermatophytosis of groin and perianal area Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/10—Animals; Substances produced thereby or obtained therefrom
- A01N63/14—Insects
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
Definitions
- the present invention relates to the field of treatments against biofilm formation and fungal and bacterial growth, and more particularly, to utilizing modified black soldier fly larvae (MBSFL) oil with released medium chain fatty acids (MCFAs), mainly lauric acid, in the form of laurate (e.g., sodium laurate, potassium laurate etc.), monolaurin and/or free lauric acid.
- MFSFL modified black soldier fly larvae
- MCFAs medium chain fatty acids
- BSFL Black soldier fly ( Hermetia illucens ) larvae (BSFL) are rich in fat, with levels ranging between 15% and 49% on dry matter basis.
- the fatty acid profile of the prepupae is high in the medium-chain fatty acids (MCFAs), with lauric acid (02:0) being the major component. Lauric acid is known to have profound antiviral, antifungal and antibacterial activity, and particularly to be active against Gram positive bacteria.
- the fatty acid profile of the prepupae contains additional MCFAs such as capric acid (00:0) and caprylic acid (C8:0).
- Lauric acid in insect larvae is stored mainly as triglycerides (Liland et al. 2017, Modulation of nutrient composition of black soldier fly ( Hermetia illucen ) larvae by feeding seaweed-enriched media, PLoS ONE 12(8): eOl 83188, incorporated herein by reference in its entirety).
- triglycerides There are several ways known in the industry to break triglycerides into monoglycerides and free fatty acids to enhance its antimicrobial properties. For example, in WIPO Publication No. 2007067028, incorporated herein by reference in its entirety, coconut oil and palm kernel were hydrolyzed using a catalytic activity of 1,3 positional specific lipases.
- the modified oil compositions comprised of free fatty acids (>9.4%), monoglycerides (>1.3%), diglycerides (>22.8%) and triglycerides (>25%), were able to inhibit the growth of Gram-positive bacteria, e.g., Staphylococcus aurous aureus, Listeria monocytogenes, Sterptococcus pyogene, Gram-negative bacteria, e.g., Vibrio cholerae, Escherichia coli and yeast, e.g., Candida albicans.
- Gram-positive bacteria e.g., Staphylococcus aurous aureus, Listeria monocytogenes, Sterptococcus pyogene
- Gram-negative bacteria e.g., Vibrio cholerae, Escherichia coli and yeast, e.g., Candida albicans.
- Fatty acids and monoglycerides produce their killing/inactivating effects by several mechanisms.
- An early postulated mechanism was the perturbing of the plasma membrane lipid bilayer.
- the antiviral action attributed to monolaurin is that of fluidizing the lipids and phospholipids in the envelope of the vims, causing the disintegration of the microbial membrane.
- More recent studies indicate that one antimicrobial effect in bacteria is related to monolaurin's interference with signal transduction/toxin formation (Projan, et al. 1994, Glycerol monolaurate inhibits the production of Blactamase, toxic shock syndrome toxin- 1, and other staphylococcal exoproteins by interfering with signal transduction.
- One aspect of the present invention provides a method comprising extracting black soldier fly larvae (BSFL) oil by processing BSFL, modifying the BSFL oil into modified BSFL (MBSFL) oil by converting triglycerides in the BSFL oil to monoglycerides, fatty acid salts and/or free fatty acids (FFA) of medium chain fatty acids (MCFAs), and applying the MBSFL oil to suppress biofilm development and/or microorganism growth.
- BSFL black soldier fly larvae
- MBSFL modified BSFL
- FFA free fatty acids
- MCFAs medium chain fatty acids
- One aspect of the present invention provides a system comprising a processing unit configured to extract black soldier fly larvae (BSFL) oil from BSFL, a conversion unit configured to convert triglycerides in the prepared BSFL oil into monoglycerides, fatty acid salts and/or FFA of medium chain fatty acids (MCFAs) to yield modified black soldier fly larvae (MBSFL) oil, and a formulation unit configured to prepare from the MBSFL oil a formulation that suppresses biofilm development and/or microorganism growth.
- BSFL black soldier fly larvae
- MCFAs medium chain fatty acids
- One aspect of the present invention provides a topical dermal or oral composition, comprising modified black soldier fly larvae (MBSFL) oil, modified from BSFL oil extracted from processed BSFL and comprising monoglycerides, fatty acid salts and/or FFA of medium chain fatty acids (MCFAs) converted from triglycerides in the BSFL oil.
- MFSFL black soldier fly larvae
- BSFL oil extracted from processed BSFL and comprising monoglycerides, fatty acid salts and/or FFA of medium chain fatty acids (MCFAs) converted from triglycerides in the BSFL oil.
- MCFAs medium chain fatty acids
- Figure 1 is a high-level schematic flowchart illustration of a method, according to some embodiments of the invention.
- Figure 2 is a high-level schematic illustration of a system, according to some embodiments of the invention.
- Figure 3 provides results indicating the effect of BSFL oil on Pseudomonas aeruginosa (PAOl) growth in planktonic environment, according to some embodiments of the invention.
- PAOl Pseudomonas aeruginosa
- Figures 4A-F provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on the growth of various types of microorganisms in planktonic environment, specifically Pseudomonas aeruginosa (PAOl, Figure 4A), Staphylococcus aureus (SA, Figure 4B), Streptococcus mutans (SM, Figure 4C), Lactobacillus (L, Figure 4D), Candida albicans (CA, Figure 4E) and Candida glabrata (CG, Figure 4F), according to some embodiments of the invention.
- PAOl Pseudomonas aeruginosa
- SA Staphylococcus aureus
- SM Streptococcus mutans
- L Lactobacillus
- CA Candida albicans
- CA Candida albicans
- CG Candida glabrata
- Figure 5 provides results indicating the effect of BSFL oil on biofilm formation of Staphylococcus aureus (SA), according to some embodiments of the invention.
- Figures 6A-E provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 6A), Staphylococcus aureus (SA, Figure 6B), Streptococcus mutans (SM, Figure 6C), Candida albicans (CA, Figure 6D) and Candida glabrata (CG, Figure 6E), according to some embodiments of the invention.
- PAOl Pseudomonas aeruginosa
- SA Staphylococcus aureus
- SM Streptococcus mutans
- CA Candida albicans
- CG Candida glabrata
- Figures 7A-F provide comparative results indicating the effect of chlorhexidine acetate (CHX) on planktonic growth and biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 7A), Staphylococcus aureus (SA, Figure 7B), Streptococcus mutans (SM, Figure 7C), Lactobacillus (L, Figure 7D), Candida albicans (CA, Figure 7E) and Candida glabrata (CG, Figure 7F), according to some embodiments of the invention.
- Pseudomonas aeruginosa PAOl, Figure 7A
- SA Staphylococcus aureus
- SM Streptococcus mutans
- L Lactobacillus
- CA Candida albicans
- CA Candida albicans
- CG Candida glabrata
- Embodiments of the present invention provide efficient and economical methods and mechanisms for modifying BSFL oil to enhance medium chain fatty acids (MCFAs) in the form of monoglycerides, fatty acid salts and/or FFA, and thereby provide improvements to the technological field of treatments against biofilm formation and fungal, viral and bacterial growth.
- Methods, formulations and production systems are provided.
- Methods comprise extracting black soldier fly larvae (BSFF) oil by processing BSFF, modifying the BSFF oil into modified BSFF (MBSFF) oil by converting triglycerides in the BSFF oil to monoglycerides, fatty acid salts and/or FFA of MCFAs, e.g., by saponification and/or hydrolysis, and applying the MBSFF oil to suppress biofilm development and/or microorganism growth (e.g., of Gram-positive and/or Gram-negative bacteria, fungi and possibly viruses).
- Applications of the MBSFF oil include dermal, topical and/or oral applications, as well as applications to medical equipment and industrial pipework.
- FIG. 1 is a high-level schematic flowchart illustration of a method 100, according to some embodiments of the invention.
- Method 100 may comprise the following stages, irrespective of their order.
- Method 100 comprises extracting black soldier fly larvae (BSFF) oil by processing BSFF (stage 110), modifying the BSFF oil into modified BSFF (MBSFF) oil by converting triglycerides in the BSFF oil to monoglycerides, fatty acid salts and/or FFA of MCFAs (stage 120), and applying the MBSFF oil to suppress biofilm development and/or microorganism growth (stage 140), e.g., of bacteria, fungi, viruses and/or protozoa.
- BSFF black soldier fly larvae
- MFSFF modified BSFF
- stage 140 biofilm development and/or microorganism growth
- BSFF oil extraction 110 may precede BSFF oil conversion 120 and/or conversion of triglycerides 120 in the BSFF may precede BSFF oil extraction 110, in which case the extracted BSFF oil may already be enriched with MCFAs.
- the MCFAs may comprise mainly lauric acid, for example in the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid.
- typically BSFL oil comprises clear fat (e.g., having >99% fat), that contains ca. 45% lauric acid (as a non-limiting example) in the form of triglycerides, which are modified in MBSFL oil to the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid.
- the extraction process of the oil from the BSFL leaves behind the rest of the biomass of the larvae termed "BSF meal", "BSFL meal” or “protein meal”, which contains only 5- 15% oil, which, if converted, may comprise ca. 40% lauric acid in the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid.
- different oil levels may be produced in both BSFL/MBSFL oils and BSFL meal, and, in case the latter comprises a large oil portion, it may too be converted into monoglycerides, fatty acid salts and/or FFA of MCFAs for various applications (see an example below).
- converting triglycerides in the BSFL oil to monoglycerides, fatty acid salts and/or FFA of MCFAs 120 may be carried out by saponification and/or hydrolysis (stage 122). Hydrolysis may comprise acidic and/or enzymatic hydrolysis. In certain embodiments, method 100 may comprise enhancing the solubility of the converted MBSFL oil with respect to the BSFL oil (stage 124), as disclosed below. Conversion 120 may comprise breaking off fatty acids from triglyceride fats in the BSFL oil to form mono glycerides and/or free fatty acids and/or fatty acid salts of MCFAs to exert the antimicrobial and/or antibiofilm activity.
- method 100 may further comprise separating the MCFAs from the glycerol in the MBSFL oil and applying the extracted MCFAs to suppress biofilm development and/or microorganism growth (stage 125).
- method 100 may comprise enriching the MBSFL oil with MCFAs (stage 130), possibly separated from MBSFL oil.
- method 100 may comprise preparing the MBSFL oil to include additional antimicrobial fatty acids (stage 132), e.g., preparing the MBSFL oil to comprise a combination of MCFAs lauric acid (02:0) and capric acid (00:0) with optional antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06:1), oleic acid (08:1), linoleic acid (08:2) and/or alpha linolenic acid (08:3), converted by saponification and/or hydrolysis from the respective fatty acid triglycerides - to yield antimicrobial and antibiofilm properties.
- additional antimicrobial fatty acids stage 132
- Method 100 may comprise applying the MBSFL oil to suppress biofilm development and/or microorganism growth in a wide range of applications.
- applying the MBSFL oil 140 may be carried out against any of Gram-positive bacterial biofilms, Gram-negative bacterial biofilms, fungal biofilms and/or growth of micro-organisms such as fungi, protozoa, bacteria and/or viruses.
- applying the MBSFL oil 140 may be carried out in any of dermal, topical and/or oral applications (see examples below); for disinfecting medical equipment such as catheters; and/or in industrial applications such as disinfecting pipes.
- compositions or formulations comprising MBSFL oil, modified from BSFL oil extracted from processed BSFL and comprising monoglycerides, fatty acid salts and/or FFA of MCFAs converted from triglycerides in the BSFL oil.
- the compositions or formulations may comprise topical dermal and/or oral formulations.
- the compositions or formulations may comprise compositions for disinfecting medical equipment such as catheters and/or industrial pipework.
- FIG. 2 is a high-level schematic illustration of a system 200, according to some embodiments of the invention.
- System 200 comprises an extraction unit 210 configured to extract BSFL oil 215 from BSFL 90, a conversion unit 220 configured to convert triglycerides in prepared BSFL oil 215 into monoglycerides, fatty acid salts and/or FFA of MCFAs - to yield modified black soldier fly larvae (MBSFL) oil 225, and a formulation unit 240 configured to prepare from MBSFL oil 225 a formulation 245 that suppresses biofilm development and/or microorganism growth 260, e.g., of bacteria, fungi, viruses and/or protozoa.
- the MCFAs may comprise mainly lauric acid, for example in the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid.
- BSFL 90 were used as raw material, after drying to a moisture content of less than 3%, to extract oil therefrom using a mechanical press (expeller).
- solvent extraction e.g., using hexane, petroleum ether, water
- MBSFL oil 225 was prepared using a saponification process (by which triglycerides are reacted with sodium or potassium hydroxide to produce glycerol and a fatty acid salt).
- BSFL oil 215 was heated to 60-70°C.
- KOH was mixed with bi-distilled water at a 1 :3 ratio accordingly, and then mixed with heated BSFL oil 215 in a ratio according to its saponification number, which was set to 19.9% (2500g BSFL oil, 1500g bi-distilled H20, 497.5g KOH analytical). In another example, a similar mixture was prepared, but with an excess amount of KOH (5% more than indicated according to the saponification number). In the data below resulting MBSFL oil 225 (indicated as lot 0030.111217-181125) compared to the source BSFL oil 215 (indicated as lot 0030.111217).
- Table 1 provides results of triacylglycerols (TAG), diacylglycerols (DAG) and monoacylglycerols (MAG) composition, and Free Fatty Acids (FFA) for BSFL oil and converted, MBSFL oil.
- TAG triacylglycerols
- DAG diacylglycerols
- MAG monoacylglycerols
- FFA Free Fatty Acids
- BSFL oil glycerides composition contains mainly TAG, with no DAG or MAG detected.
- the saponification process increased MAG composition in the sample to 7.3 (g/lOOg Oil), dominated by the dodecanoic (lauric) acid monoglyceride (2.39 g/lOOg Oil).
- Table 1 TAG, DAG and MAG composition and FFA content in BSFL oil before and after conversion (test method for DAG, MAG composition: MP 0118 REV3 2012; Test method for TAG composition: REG CE 273/2008; Test method for FFA: AOCS Ca 5a-40).
- Table 2 provides data of the fatty acids profile of the MBSFL oil.
- Laurie acid, 02:0 is the major component of medium-chain fatty acids (MCFAs) found in the MBSFL oil (45.48 g/lOOg oil), however, MBSFL oil contains additional MCFA capric acid, 00:0 (1.03g/100g oil).
- MBSFL oil contains additional fatty acids such as n-6 linoleic acid, 08:2 (10.7603g/100g oil), n-7 palmitoleic acid, 06:1 (3.09g/100g oil) and n-9 oleic acid, 08:1 (12.5303g/100g oil).
- fatty acids were found to exert significant antimicrobial activity against various microorganisms such as oral pathogens Streptococcus mutans, Candida albicans, Aggregatibacter actinomycetemcomitans , Fusobacterium nucleatum, and Porphyromonas gingivalis (Fluang 2010, Antimicrobial activity of n- 6, n-7 and n-9 fatty acids and their esters for oral microorganisms, Arch Oral Biol, 55(8): 555-560; Dilika et al.
- MBSFL oil contains 0.77g/100g oil n-3 alpha linolenic acid (Cl 8:3).
- alpha linolenic acid and its ester derivatives exhibited strong antibacterial activity against various oral pathogens, including S. mutans, C. albicans, A. actinomycetemcomitans, F. nucleatum, and P. gingivalis (Huang et al.
- MBSFL oil contains also 10.19g/100g oil myristic acid (Cl 4:0) which was shown to inhibit the growth of the Gram positive bacterium, L. monocytogenes (Chen et al. 2019; Antimicrobial potential of myristic acid against Listeria monocytogenes in milk; The Journal of Antibiotics 72:298-305).
- MCFAs lauric acid (02:0) and capric acid (00:0) with potential antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06: 1), oleic acid (08:1), linoleic acid (08:2) and/or alpha linolenic acid (C18:3) also composing the MBSFL oil and undergo the conversion process (saponification) contributes to the overall antimicrobial and antibiofilm properties of the MBSFL oil.
- Table 2 Fatty acid profile of BSFL oil before and after conversion (MBSFL oil). Test methods: EN 12966-2, EN 12966-1 and EN 12966-4.
- MBSFL oil 225 may comprise a combination of MCFAs lauric acid (02:0) and capric acid (00:0) with optional antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06:1), oleic acid (08:1), linoleic acid (08:2) and/or alpha linolenic acid (08:3), converted by saponification and/or hydrolysis from the respective fatty acid triglycerides - to yield antimicrobial and antibiofilm properties.
- optional antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06:1), oleic acid (08:1), linoleic acid (08:2) and/or alpha linolenic acid (08:3) converted by saponification and/or hydrolysis from the respective fatty acid triglycerides - to yield antimicrobial and antibiofilm properties.
- extraction unit 210 and conversion unit 220 may be operated in reversed order, or possibly in parallel, so that the triglycerides are converted into monoglycerides, fatty acid salts and/or FFA of MCFAs already in BSF larvae 90 and prior to separation of (MCFAs-rich) BSFL oil as MBSFL oil 225.
- conversion unit 220 may be configured to convert the triglycerides into monoglycerides, fatty acid salts and/or FFA of MCFAs by saponification and/or hydrolysis (e.g., acidic or enzymatic).
- Conversion unit 220 may be configured to break off fatty acids from triglyceride fats in BSFL oil 215 to form monoglycerides and/or free fatty acids and/or fatty acid salts that exert the antimicrobial activity.
- BSFL 90 may be grinded and blanched and/or heated, the pH of the resulting slurry may be adjusted, and the slurry may then be subjected to lipolytic enzymes such as lipase, to increase free lauric acid fractions (releasing lauric acid from the triglyceride complex).
- lipolytic enzymes such as lipase
- the slurry may then be heated to inactivate the enzymes and the slurry may be separated into its oil, protein and water fractions, e.g., using a decanter and/or a centrifuge.
- the lipase enzymes may be added after the separation stage, to the oil fraction and/or to the meal fraction separately.
- the slurry may be dried to produce whole fat insect meal with modified oil having increased antimicrobial properties.
- the remaining meal fraction may have high oil content (e.g., 10% or more) and may be further treated to yield additional laurate, monolaurin and/or free lauric acid-enriched products.
- lipolytic enzymes may be used to decompose the lipids, e.g., as taught by Japanese Patent Publication No. 2009254348 for processing bee larvae.
- MBSFL oil 225 may be rich in monolaurin and free lauric acid and/or laurate, and as a result have antimicrobial properties for a wide range of applications, without requiring the digestion of BSFL oil with triglycerides by animals that is taught in the prior art.
- system 200 may further comprise a separation unit 230 configured to separate MCFAs 235 from MBSFL oil 225 and optionally enrich MBSFL oil 225 with extracted MCFAs 235.
- a separation unit 230 configured to separate MCFAs 235 from MBSFL oil 225 and optionally enrich MBSFL oil 225 with extracted MCFAs 235.
- SC-CO2 fractional supercritical carbon dioxide
- glycerol fraction can be extracted out, leaving behind MCFAs rich fraction together with additional essential fatty acids.
- separation unit 230 may be configured to separate out glycerol from the MBSFL oil to yield MCFAs-rich MBSFL oil.
- formulation 245 may be configured to suppress any of Gram positive bacterial biofilms, Gram-negative bacterial biofilms, fungal biofilms and/or growth of microorganisms.
- formulation 245 may be configured to be applicable in at least one of: Dermal applications, topical therapy, oral applications, medical equipment and/or industrial applications (see examples below). In certain embodiments, formulation 245 may be configured to prepare the formulation as a dermal or oral creme, semm, wash, suspension and/or solution, or any other type of formulation. In certain embodiments, system 200 may further comprise an applicator 250, such as any appropriate device like a dispenser, collapsible container, sprayer etc., configured to apply formulation 245.
- an applicator 250 such as any appropriate device like a dispenser, collapsible container, sprayer etc., configured to apply formulation 245.
- the conversion process may be configured to enhance BSFL oil dissolution in water, resulting in MBSFL oil with improved solubility with respect to BSFL oil.
- low water solubility of a substance may sometimes be used to modify its relative antimicrobial inactivity (Griffin et al., 1999, The role of structure and molecular properties of terpenoids in determining their antimicrobial activity; Flavour and Fragrance Journal 14(5): 322-332).
- solubility could well be a limiting factor with respect to practical applications.
- Table 3 provides solubility data for BSFL oil before and after the saponification (conversion) process.
- Table 3 Solubility data of BSFL oil, before and after conversion to MBSFL oil. Test method: Food Chemicals Codex (FCC).
- MBSFL oil (converted, 225, BioBee Sde Eliyahu Ltd, lot 0095-0098.181210-181227) was compared to BSFL oil (before conversion, 215, BioBee Sde Eliyahu Ltd, lot 0030.111217), lauric acid 98% (Sigma-Aldrich, denoted LA) and chlorhexidine acetate (Steinberg, denoted CHX), were analyzed as antimicrobial and anti-biofilm- formation agents in vitro, with respect to Pseudomonas aeruginosa (Gram negative, denoted PA01), Staphylococcus aureus (ATCC, American Type Culture Collection) (Gram positive, denoted SA), Streptococcus mutans (ATCC) (Gram positive, denoted SM), Lactobacillus (ATCC) (Gram
- Microbial stocks of the Biofilm Research Laboratory were grown from frozen stock: SM at overnight 37°C in BHI (brain heart infusion) broth medium in an atmosphere of 5% CO2; L at 37°C in MRS (de Man, Rogosa and Sharpe) broth medium in an atmosphere of 5% CO2; PAOl and SA at 37°C in TSB (Trypticase soy broth) medium; CA and CG at 37°C in RPMI (Roswell Park Memorial Institute) medium.
- BHI brain heart infusion
- MRS de Man, Rogosa and Sharpe
- PAOl and SA at 37°C in TSB (Trypticase soy broth) medium
- CA and CG at 37°C in RPMI (Roswell Park Memorial Institute) medium.
- BSFL oil and MBSFL oil were prepared in DDW by heating at 100°C.
- LA was prepared at 50% Ethanol / 50% DDW (doubly distillated water) and heated constantly to prevent solidifying in the tube. Maximum concentration of tested agents was the same (2.7% of lauric acid content).
- CHX was prepared in DDW
- serial 1 :2 dilutions of each tested agent in appropriate medium were prepared in a polystyrene flat-bottomed 96-well microplate. Wells with no compounds and those with bacteria served as positive controls. Wells with no bacteria and with compound served as blanks.
- An equal volume (100 m ⁇ ) of the each tested bacterial and fungal suspension at optical density (OD) 595 0.02 and 0.05, respectively, was added to each well. After a 24 h incubation, growth was monitored by recording the OD at 595 nm using a Genius plate reader Spectrophotometer (Tecan). The assay was performed in triplicates.
- MBSFL oil was plated on agar plates. Plates were incubated overnight at 37°C. Colony growth was recorded as non-affected by agent's viable bacteria.
- MBC Bactericidal Concentration
- MFC Minimal Fungicidal Concentration
- Figure 3 provides results of the effect of BSFL oil on Pseudomonas aeruginosa (PAOl) growth in planktonic environment, according to some embodiments of the invention.
- the means and standard deviations of the bacterial growth are shown, and significant differences (from no BSFL oil, p ⁇ 0.01) according to Student’s t-test are denoted be asterisks (*).
- No minimum inhibitory concentration (MIC) was detected, however, PAOl growth was reduced dose-dependently with increasing BSFL oil doses.
- BSFL oil at doses of 0.28%, 0.56%, 1.12% and 2.25% was able to decrease PAOl growth by 23%, 37%, 55% and 60%, respectively.
- Figures 4A-F provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on the growth of various types of microorganisms in planktonic environment, specifically Pseudomonas aeruginosa (PAOl, Figure 4A), Staphylococcus aureus (SA, Figure 4B), Streptococcus mutans (SM, Figure 4C), Lactobacillus (L, Figure 4D), Candida albicans (CA, Figure 4E) and Candida glabrata (CG, Figure 4F), according to some embodiments of the invention.
- PAOl Pseudomonas aeruginosa
- SA Staphylococcus aureus
- SM Streptococcus mutans
- L Lactobacillus
- CA Candida albicans
- CA Candida albicans
- CG Candida glabrata
- Figure 4B, 4C, 4D, 4E and 4F illustrate the effect of MBSFL oil in comparison with LA on planktonic growth for SA, SM, L, CA and CG, respectively.
- Both MBSFL oil and LA dramatically affected growth of SA: LA already at lowest tested dose of 0.04 % reduced SA growth by 90%, while MBSFL in range of doses 0.04 %-0.67 % reduced bacterial growth by 75%, exhibiting MIC at dose of 1.35% (Figure 4B).
- MBSFL oil moderately reduced SM growth, however it did not exhibit either MIC or MBC.
- LA notably decreased bacterial growth and was able to exhibit MIC at dose of 0.33% (Figure 4C).
- MBSFL oil results show growth inhibition effect, no MBC/MFC was detected for MBSFL oil at all tested doses for all of the microorganisms tested: PAOl, SA, SM, CA and CG. Only exception is with L, for which MBC for MBSFL oil was less than 0.08%. Whereas MBC/ MFC for MBSFL oil was detected for one microbe only, LA exerted MBC/ MFC for all tested microbes, except PAOl : MBC for SA was detected at dose of 0.67%, MBC for SM was detected at dose of 0.33%, MBC for L was detected at dose of 0.67%, MFC for both CA and CG was detected at dose of 2.7%.
- Figure 5 provides comparative results indicating the effect of BSFL oil on biofilm formation of Staphylococcus aureus (SA), according to some embodiments of the invention.
- Unmodified BSFL oil caused insignificant effect on biofilm formation, affecting only SA by a moderate decrease of biofilm formation in the range of 20%-29%.
- biofilm formation of the rest of microbes was not affected by BSFL oil, data are not shown.
- Figures 6A-E provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 6A), Staphylococcus aureus (SA, Figure 6B), Streptococcus mutans (SM, Figure 6C), Candida albicans (CA, Figure 6D) and Candida glabrata (CG, Figure 6E), according to some embodiments of the invention.
- Figures 6A-6E illustrate that the modification of BSFL oil increased its antibiofilm properties.
- MBSFL oil demonstrated a much more pronounced effect on biofilm formation of all tested microbes as compared to LA: MBSFL oil at doses of up to 0.33% increased biomass of PAOl, while increasing MBSFL oil doses starting from 0.67% inhibition of biofilm formation. MBSFL oil at doses of 1.35% and 2.7 % almost totally inhibited biofilm formation. In contrast, LA dose-dependently increased biomass at all concentrations tested ( Figure 6A). Biofilm formation of SA was dramatically inhibited by MBSFL oil already at lowest tested dose of 0.04% (almost no biofilm was formed), while LA was able dose-dependently to decrease biofilm formation and at 0.67% was totally inhibited biofilm formation (Figure 6B).
- Figures 7A-F provide comparative results indicating the effect of chlorhexidine acetate (CHX) on planktonic growth and biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 7A), Staphylococcus aureus (SA, Figure 7B), Streptococcus mutans (SM, Figure 7C), Lactobacillus (L, Figure 7D), Candida albicans (CA, Figure 7E) and Candida glabrata (CG, Figure 7F), according to some embodiments of the invention.
- Pseudomonas aeruginosa PAOl, Figure 7A
- SA Staphylococcus aureus
- SM Streptococcus mutans
- L Lactobacillus
- CA Candida albicans
- CA Candida albicans
- CG Candida glabrata
- the positive control agent, CHX exhibited total inhibition of P AO 1 growth and biofilm formation at the same dose of 10 pg/ml ( Figure 7A), MBC was detected at dose of 20 pg/ml. CHX inhibited growth and biofilm formation of SA at the same dose of 2.5 pg/ml ( Figure 7B), MBC was detected at dose of 10 pg/ml. CHX inhibited growth, biofilm formation and exhibited MBC against SM at the same dose of 0.625 pg/ml ( Figure 7C). MIC and MBC for CHX against L were detected at the same dose of 2.5 pg/ml ( Figure 7D). Since biofilm of L was very weak and easily washed out, no data were demonstrated on biofilm formation.
- CHX inhibited growth and biofilm formation of CA and CG and exhibited MFC at the same dose of 5 pg/ml and 2.5 pg/ml ( Figures 7E and 7F, respectively). CHX serves as a positive control, demonstrating a non-specific killing effect.
- MBSFL oil (converted, 225, BioBee Sde Eliyahu Ltd, lot 0095-0098.181210-181227) was tested in vitro in comparison with the antifungal dmgs Bifonazole and Terbinafine.
- MBSFL oil was prepared in DDW at a 1 :1 ratio by heating and stirring at 100°C. Bifonazole and Terbinafine were used as is.
- Tables 4A and 4B provide experimental results indicating the antifungal efficiency of MBSFL oil, according to some embodiments of the invention.
- Table 4A provides comparative results indicating the effect of MBSFL oil, Bifonazole and Terbinafine on the growth of T. rubrum, M. canis and E. floccosum. MBSFL oil exhibited full growth inhibition against all fungi tested, similar to Bifonazole and Terbinafine at the specific concentration tested.
- Table 4B provides experimental results comparing MBSFL oil to Terbinafine hydrochloride 1% % w/w in spray topical formulation (Lamisil®) in their efficiency to inhibit Trichophyton rubrum growth. Fungal growth was monitored over two weeks in petri dishes containing dissolved SDA (Sabouraud Dextrose Agar) substrate with T. rubrum samples.
- SDA Sud Dextrose Agar
- Table 4A The effect of antifungal agents against T. rubrum, M. canis and E. floccosum growth vs. time.
- Table 4B Experimental results comparing MBSFL oil to Terbinafine hydrochloride 1% (Lamisil®) asinhibitors of T. rubrum growth.
- MBSFL oil at 4% concentration inhibits T. rubrum growth in vitro as good as the known antifungal agent Lamisil®, indicating it being a potent anti-fungal agent.
- the anti-fungal activity of MBSFL oil in this experiments was dose dependent, with low concentrations (1%) not being active.
- Lamisil® is used to treat tinea pedis (athlete's foot) and tinea cmris (dhobie itch/jock itch) caused by Trichophyton (e.g., T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum ) and Epidermophyton floccosum, there are good grounds to suggest that MBSFL oil is likewise efficient in treating tinea pedis and related fungal infections in dermatological and non- dermatological diseases.
- the concentration of the MBSFL oil for inhibiting growth of micro-organisms is not limited to the values shown in the experiments above. Specifically, the required MBSFL oil concentrations depend on the composition of specific types of MBSFL oil, on the type(s) of micro- organism(s) of which growth is to be inhibited and on the conditions of the application. For example, the MBSFL oil was shown in preliminary experiments to inhibit growth of Candida albicans at a concentration of about 0.3%. Accordingly, the concentration of the MBSFL oil may be any of at least 0.1%, 0.3%, 0.5%, 1%, 2%, 3%, 5%, 10% or any intermediate value or range of values.
- MBSFL oil may be used to inhibit viral growth, as disclosed above.
- vimses such as Porcine Epidemic Diarrhea Virus (PEDV), fat-enveloped viruses (e.g., Marek, Newcastle disease (ND), infectious bronchitis (IB), avian influenza (AI)), Vesicular stomatitis virus (VSV) strain Indiana, Herpes simplex virus type 1 (HSV-1) strain MacIntyre, Visna Virus (VV), Junin vims (JUNV), HIV vims and possibly Covid 19/ nCoV-2019 were shown to be inhibited by lauric acid, monolaurin, medium-chain fatty acids (MCFA) and/or coconut oil, indicating the potential anti-viral efficiency of disclosed MBSFL oil.
- PEDV Porcine Epidemic Diarrhea Virus
- ND Newcastle disease
- IB infectious bronchitis
- AI avian influenza
- VSV Vesicular stomatitis
- antiviral fatty acids may cause leakage of the viral envelope, and at higher concentrations, may cause a complete disintegration of the envelope and of the viral particles, and possibly also disintegration of the plasma membranes of tissue culture cells resulting in cell lysis and death.
- the fatty acid concentration required for maximum viral inactivation may vary and can be determined experimentally, with respect to the type of MBSFL oil and details of the application.
- the data show that the modification of the BSFL oil by converting triglycerides to monoglycerides, fatty acid salts and/or free fatty acids (FFA) of lauric acid notably enhances its antimicrobial properties, both in planktonic and biofilm environment.
- the MBSFL oil's effect on bacterial and fungal growth was similar to that of LA.
- MBSFL oil demonstrated a much more profound effect on biofilm formation for all tested microbes as compared to LA.
- MBC /MFC for MBSFL oil was detected for one microbe only.
- LA exerted MBC/ MFC for all tested microbes, except PAOl.
- Antibacterial agents are usually regarded as bactericidal if the MBC is no more than four times the MIC. Due to its strong inhibitory effect on biofilm formation with no bactericidal effect, which may reflect a unique and specific activity, MBSFL oil may be used as a specific anti-biofilm compound that is unique and applicable in many clinical applications and may be applied to additional pathogens and possibly in a sustained release delivery system.
- Non-limiting examples for possible applications of converted BSFL meal or oil, and/or lauric acid derived therefrom and/or formulations containing either preparations comprise a range of antibacterial, anti-viral and anti-fungal uses, against planktonic microorganisms and/or as anti-biofilm agents.
- dentistry applications may comprise oral cavity applications such as treatment of thrush, stomatitis and orthodontal issues or presentation of caries and plaque induced gingivitis or periodontitis.
- formulations 245 may comprise mouthwash, toothpaste, either as adjuvant or as stand-alone formulations.
- applications may comprise dermal applications such as: (i) Atopic dermatitis, psoriasis, contact dermatitis and/or diaper rash - BSFL/MBSFL oil may affect the dryness of the skin by its moisturizing properties and in addition, MBSFL oil may prevent the development of secondary infections, such as by S.
- Tinea pedis fungal infection of legs
- MBSFL oil may affect the fungal infection of the skin by its antifungal properties, and in addition, MBSFL oil may prevent the development of secondary bacterial infections, which are known to be developed in these diseases following patient scratching of the skin area, due to the itching symptom.
- Additional indications of the same family are scalp dandruff or seborrheic dermatitis, Pityriasis versicolor, cutaneous candidiasis, Tinea corporis and Tinea cruris.
- formulation 245 may be used to treat (iii) Dermatophytosis - MBSFL oil may be useful against Trichophyton rubrum fungi (T. rubrum is a dermatophyte fungus responsible for a fungal infection of the skin known as dermatophytosis), and/or (iv) Onychomycosis (Tinea unguium, nail fungal infection) - MBSFL oil may be useful for this and other dermatology indications.
- formulation 245 may be used to treat (v) acne vulgaris - In vitro studies (Nakatsuji et al.
- formulation 245 may be used to treat (vi) urinal tract infections.
- formulation 245 may be used to treat (vii) vaginal infections - MBSFL oil may be useful for treating Candida (as was indicated for both Candida albicans and Candida glabrata ) and bacterial vaginosis due to its antibacterial and antifungal effects, e.g., for treatment of vaginal dryness and for avoiding irritation, e.g., with formulation 245 used as intimal wash and/or vaginal capsules.
- formulation 245 may be used to treat (viii) ear infection (otitis externa, acute otitis media) and/or (ix) Xerosis and/or providing anti aging effects on skin - MBSFL oil may be useful for providing moisturizing effects, inhibition of skin water loss and enhancing of skin regeneration capability effects of lauric acid and linoleic acid.
- formulation 245 may be used to treat (x) Diabetic foot ulcers (DFU), being one of the most severe complications in Diabetes mellitus.
- DFU Diabetic foot ulcers
- MBSFL may be useful for treating DFU as it exerts a strong inhibitory effect on biofilm formation of both S. aureus and P. aeruginosa which are the predominant Gram-positive and Gram-negative species present in DFU, respectively (Santos et al. 2016, Guar gum as a new antimicrobial peptide delivery system against diabetic foot ulcers Staphylococcus aureus isolates, Journal of Medical Microbiology 65, 1092-1099).
- formulation 245 may be used to treat (xi) Infections on the skin caused by antibiotic resistant bacteria.
- MBSFL may be useful for treating Methicillin-resistant S. aureus (MRSA), a bacterium that causes infections in different parts of the body and is resistant to penicillin.
- formulation 245 may be used to treat (xii) oral candidiasis (caused by Candida albicans accumulation).
- formulation 245 may be used in (xiii) additional applications for local treatment with various types of viral infection related to Herpes: Herpes labialis, Herpes zoster and/or genital herpes.
- formulation 245 may be used to treat (xiv) autoimmune diseases causing thickened skin such as Scleroderma and Ichthyosis.
- formulation 245 may be used to treat (xv) various types of radiation burns, for example sunburn. Additional applications may comprise anti-biofilm coatings of catheters, implant devices, prostheses, mechanical valves, ventricular shunts, pacemakers, defibrillator, ventricular-assisted devices, Intervertebral disc and/or contact lenses to prevent device-associated infections of biofilm.
- Additional applications are industrial, such as anti-biofilm coatings on boats and/or pipes, cleaning agents for surfaces (e.g., tables) that remove bacterial infections (e.g., for hospitals, labs, kitchens, etc.).
- Additional examples for MBSFL oil applications may comprise veterinary applications as adjuvant in vaccines (fish, poultry) and topical applications in cats and dogs to promote the healing of cuts, wounds, hot spots, dry skin and hair, bites and stings, itching areas, as well as to prevent and treat yeast and fungal infections, including Candida and possibly to reduce or eliminate bad breath in dogs
- an embodiment is an example or implementation of the invention.
- the various appearances of "one embodiment”, “an embodiment”, “certain embodiments” or “some embodiments” do not necessarily all refer to the same embodiments.
- various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination.
- the invention may also be implemented in a single embodiment.
- Certain embodiments of the invention may include features from different embodiments disclosed above, and certain embodiments may incorporate elements from other embodiments disclosed above.
- the disclosure of elements of the invention in the context of a specific embodiment is not to be taken as limiting their use in the specific embodiment alone.
- the invention can be carried out or practiced in various ways and that the invention can be implemented in certain embodiments other than the ones outlined in the description above.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Insects & Arthropods (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dentistry (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
Abstract
Methods, formulations and production systems are provided. Methods comprise extracting black soldier fly larvae (BSFL) oil by processing BSFL, modifying the BSFL oil into modified BSFL (MBSFL) oil by converting triglycerides in the BSFL oil to medium chain fatty acids (MCFAs) in the form of monoglycerides, fatty acid salts and/or free fatty acids, e.g., by saponification and/or hydrolysis, and applying the MBSFL oil to suppress biofilm development and/or microorganism growth (e.g., of Gram-positive and/or Gram-negative bacteria, fungi and possibly viruses). Applications of the MBSFL oil include dermal and/or oral applications, topical therapy, as well as applications to medical equipment and industrial applications.
Description
MODIFIED BLACK SOLDIER ELY LARVAE OIL WITH MODIFIED LAURIC ACID FOR TREATMENT AGAINST BIOFILM FORMATION AND MICROORGANISM GROWTH
BACKGROUND OF THE INVENTION
1. TECHNICAL FIELD
[0001] The present invention relates to the field of treatments against biofilm formation and fungal and bacterial growth, and more particularly, to utilizing modified black soldier fly larvae (MBSFL) oil with released medium chain fatty acids (MCFAs), mainly lauric acid, in the form of laurate (e.g., sodium laurate, potassium laurate etc.), monolaurin and/or free lauric acid.
2. DISCUSSION OF RELATED ART
[0002] Black soldier fly ( Hermetia illucens ) larvae (BSFL) are rich in fat, with levels ranging between 15% and 49% on dry matter basis. Notably, the fatty acid profile of the prepupae is high in the medium-chain fatty acids (MCFAs), with lauric acid (02:0) being the major component. Lauric acid is known to have profound antiviral, antifungal and antibacterial activity, and particularly to be active against Gram positive bacteria. The fatty acid profile of the prepupae contains additional MCFAs such as capric acid (00:0) and caprylic acid (C8:0). Trials showed that black soldier fly prepupal fat (0.58g C12:0/100ml) suppressed growth of Lactobacilli, with the most substantial antibacterial effects against D-streptococci infections in pigs. In in vivo conditions it has been suggested that these positive effects are most likely seen when farming conditions and/or health status are sub-optimal (Gasco et al. 2018, Can diets containing insects promote animal health? Journal of Insects as Food and Feed 4(1): 1-4, incorporated herein by reference in its entirety).
[0003] It has also been reported that whereas medium-chain fatty acids (MCFAs), monoglycerides and free fatty acids (FFA) sourced from virgin coconut oil (VCO) exhibit antimicrobial activity, the triglycerides and diglycerides in the oil were shown to have a lesser antimicrobial activity. It has been suggested that VCO may be metabolized to release its component MCFAs, caprylic acid (C8 :0), capric acid (00:0), and lauric acid (02:0) to exert its antimicrobial effects (Shilling et al. 2013, Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on Clostridium difficile ; Journal Of Medicinal Food 16 (12), 1079-1085, incorporated herein by reference in its entirety).
[0004] Lauric acid in insect larvae is stored mainly as triglycerides (Liland et al. 2017, Modulation of nutrient composition of black soldier fly ( Hermetia illucen ) larvae by feeding seaweed-enriched
media, PLoS ONE 12(8): eOl 83188, incorporated herein by reference in its entirety). There are several ways known in the industry to break triglycerides into monoglycerides and free fatty acids to enhance its antimicrobial properties. For example, in WIPO Publication No. 2007067028, incorporated herein by reference in its entirety, coconut oil and palm kernel were hydrolyzed using a catalytic activity of 1,3 positional specific lipases. The modified oil compositions comprised of free fatty acids (>9.4%), monoglycerides (>1.3%), diglycerides (>22.8%) and triglycerides (>25%), were able to inhibit the growth of Gram-positive bacteria, e.g., Staphylococcus aurous aureus, Listeria monocytogenes, Sterptococcus pyogene, Gram-negative bacteria, e.g., Vibrio cholerae, Escherichia coli and yeast, e.g., Candida albicans.
[0005] Fatty acids and monoglycerides produce their killing/inactivating effects by several mechanisms. An early postulated mechanism was the perturbing of the plasma membrane lipid bilayer. The antiviral action attributed to monolaurin is that of fluidizing the lipids and phospholipids in the envelope of the vims, causing the disintegration of the microbial membrane. More recent studies indicate that one antimicrobial effect in bacteria is related to monolaurin's interference with signal transduction/toxin formation (Projan, et al. 1994, Glycerol monolaurate inhibits the production of Blactamase, toxic shock syndrome toxin- 1, and other staphylococcal exoproteins by interfering with signal transduction. J Bacteriology 176:4204-4209, incorporated herein by reference in its entirety). Another antimicrobial effect in vimses is due to lauric acid's interference with vims assembly and viral maturation (Hornung et al. 1994, Fauric acid inhibits the maturation of vesicular stomatitis vims; Journal of General Virology 75 (Pt 2)(2):353-61 , incorporated herein by reference in its entirety). The third mode of action may be on the immune system itself (Witcher et al. 1996, Modulation of immune cell proliferation by glycerol monolaurate. Clinical and Diagnostic Faboratory Immunology 3:10-13, incorporated herein by reference in its entirety).
[0006] Hess et al. 2015, The natural surfactant glycerol monolaurate significantly reduces development of Staphylococcus aureus and Enterococcus faecalis biofilms, Surgical Infections 16(5): 538-542, incorporated herein by reference in its entirety, teaches using the natural surfactant glycerol monolaurate (GMF) to inhibit biofilm development.
SUMMARY OF THE INVENTION
[0007] The following is a simplified summary providing an initial understanding of the invention. The summary does not necessarily identify key elements nor limit the scope of the invention, but merely serves as an introduction to the following description.
[0008] One aspect of the present invention provides a method comprising extracting black soldier fly larvae (BSFL) oil by processing BSFL, modifying the BSFL oil into modified BSFL (MBSFL) oil by converting triglycerides in the BSFL oil to monoglycerides, fatty acid salts and/or free fatty acids (FFA) of medium chain fatty acids (MCFAs), and applying the MBSFL oil to suppress biofilm development and/or microorganism growth.
[0009] One aspect of the present invention provides a system comprising a processing unit configured to extract black soldier fly larvae (BSFL) oil from BSFL, a conversion unit configured to convert triglycerides in the prepared BSFL oil into monoglycerides, fatty acid salts and/or FFA of medium chain fatty acids (MCFAs) to yield modified black soldier fly larvae (MBSFL) oil, and a formulation unit configured to prepare from the MBSFL oil a formulation that suppresses biofilm development and/or microorganism growth.
[0010] One aspect of the present invention provides a topical dermal or oral composition, comprising modified black soldier fly larvae (MBSFL) oil, modified from BSFL oil extracted from processed BSFL and comprising monoglycerides, fatty acid salts and/or FFA of medium chain fatty acids (MCFAs) converted from triglycerides in the BSFL oil.
[0011] These, additional, and/or other aspects and/or advantages of the present invention are set forth in the detailed description which follows; possibly inferable from the detailed description; and/or leamable by practice of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] For a better understanding of embodiments of the invention and to show how the same may be carried into effect, reference will now be made, purely by way of example, to the accompanying drawings in which like numerals designate corresponding elements or sections throughout.
[0013] In the accompanying drawings:
[0014] Figure 1 is a high-level schematic flowchart illustration of a method, according to some embodiments of the invention.
[0015] Figure 2 is a high-level schematic illustration of a system, according to some embodiments of the invention.
[0016] Figure 3 provides results indicating the effect of BSFL oil on Pseudomonas aeruginosa (PAOl) growth in planktonic environment, according to some embodiments of the invention.
[0017] Figures 4A-F provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on the growth of various types of microorganisms in planktonic environment, specifically Pseudomonas aeruginosa (PAOl, Figure 4A), Staphylococcus aureus (SA, Figure 4B), Streptococcus mutans (SM, Figure 4C), Lactobacillus (L, Figure 4D), Candida albicans (CA, Figure 4E) and Candida glabrata (CG, Figure 4F), according to some embodiments of the invention.
[0018] Figure 5 provides results indicating the effect of BSFL oil on biofilm formation of Staphylococcus aureus (SA), according to some embodiments of the invention.
[0019] Figures 6A-E provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 6A), Staphylococcus aureus (SA, Figure 6B), Streptococcus mutans (SM, Figure 6C), Candida albicans (CA, Figure 6D) and Candida glabrata (CG, Figure 6E), according to some embodiments of the invention.
[0020] Figures 7A-F provide comparative results indicating the effect of chlorhexidine acetate (CHX) on planktonic growth and biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 7A), Staphylococcus aureus (SA, Figure 7B), Streptococcus mutans (SM, Figure 7C), Lactobacillus (L, Figure 7D), Candida albicans (CA, Figure 7E) and Candida glabrata (CG, Figure 7F), according to some embodiments of the invention.
DETAILED DESCRIPTION OF THE INVENTION
[0021] In the following description, various aspects of the present invention are described. For purposes of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the present invention. However, it will also be apparent to one skilled in the art that the present invention may be practiced without the specific details presented herein. Furthermore, well known features may have been omitted or simplified in order not to obscure the present invention. With specific reference to the drawings, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details
of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
[0022] Before at least one embodiment of the invention is explained in detail, it is to be understood that the invention is not limited in its application to the details of constmction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is applicable to other embodiments that may be practiced or carried out in various ways as well as to combinations of the disclosed embodiments. Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
[0023] Embodiments of the present invention provide efficient and economical methods and mechanisms for modifying BSFL oil to enhance medium chain fatty acids (MCFAs) in the form of monoglycerides, fatty acid salts and/or FFA, and thereby provide improvements to the technological field of treatments against biofilm formation and fungal, viral and bacterial growth. Methods, formulations and production systems are provided. Methods comprise extracting black soldier fly larvae (BSFF) oil by processing BSFF, modifying the BSFF oil into modified BSFF (MBSFF) oil by converting triglycerides in the BSFF oil to monoglycerides, fatty acid salts and/or FFA of MCFAs, e.g., by saponification and/or hydrolysis, and applying the MBSFF oil to suppress biofilm development and/or microorganism growth (e.g., of Gram-positive and/or Gram-negative bacteria, fungi and possibly viruses). Applications of the MBSFF oil include dermal, topical and/or oral applications, as well as applications to medical equipment and industrial pipework.
[0024] Figure 1 is a high-level schematic flowchart illustration of a method 100, according to some embodiments of the invention. Method 100 may comprise the following stages, irrespective of their order. Method 100 comprises extracting black soldier fly larvae (BSFF) oil by processing BSFF (stage 110), modifying the BSFF oil into modified BSFF (MBSFF) oil by converting triglycerides in the BSFF oil to monoglycerides, fatty acid salts and/or FFA of MCFAs (stage 120), and applying the MBSFF oil to suppress biofilm development and/or microorganism growth (stage 140), e.g., of bacteria, fungi, viruses and/or protozoa. In various embodiments, BSFF oil extraction 110 may precede BSFF oil conversion 120 and/or conversion of triglycerides 120 in the BSFF may precede BSFF oil extraction 110, in which case the extracted BSFF oil may already be enriched with MCFAs.
[0025] It is noted that the MCFAs may comprise mainly lauric acid, for example in the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid.
[0026] It is further noted that typically BSFL oil comprises clear fat (e.g., having >99% fat), that contains ca. 45% lauric acid (as a non-limiting example) in the form of triglycerides, which are modified in MBSFL oil to the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid. The extraction process of the oil from the BSFL leaves behind the rest of the biomass of the larvae, termed "BSF meal", "BSFL meal" or "protein meal", which contains only 5- 15% oil, which, if converted, may comprise ca. 40% lauric acid in the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid. In various embodiments, different oil levels may be produced in both BSFL/MBSFL oils and BSFL meal, and, in case the latter comprises a large oil portion, it may too be converted into monoglycerides, fatty acid salts and/or FFA of MCFAs for various applications (see an example below).
[0027] In certain embodiments, converting triglycerides in the BSFL oil to monoglycerides, fatty acid salts and/or FFA of MCFAs 120 may be carried out by saponification and/or hydrolysis (stage 122). Hydrolysis may comprise acidic and/or enzymatic hydrolysis. In certain embodiments, method 100 may comprise enhancing the solubility of the converted MBSFL oil with respect to the BSFL oil (stage 124), as disclosed below. Conversion 120 may comprise breaking off fatty acids from triglyceride fats in the BSFL oil to form mono glycerides and/or free fatty acids and/or fatty acid salts of MCFAs to exert the antimicrobial and/or antibiofilm activity.
[0028] In certain embodiments, method 100 may further comprise separating the MCFAs from the glycerol in the MBSFL oil and applying the extracted MCFAs to suppress biofilm development and/or microorganism growth (stage 125). In certain embodiments, method 100 may comprise enriching the MBSFL oil with MCFAs (stage 130), possibly separated from MBSFL oil. In certain embodiments, method 100 may comprise preparing the MBSFL oil to include additional antimicrobial fatty acids (stage 132), e.g., preparing the MBSFL oil to comprise a combination of MCFAs lauric acid (02:0) and capric acid (00:0) with optional antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06:1), oleic acid (08:1), linoleic acid (08:2) and/or alpha linolenic acid (08:3), converted by saponification and/or hydrolysis from the respective fatty acid triglycerides - to yield antimicrobial and antibiofilm properties.
[0029] Method 100 may comprise applying the MBSFL oil to suppress biofilm development and/or microorganism growth in a wide range of applications. In various embodiments, applying the MBSFL oil 140 may be carried out against any of Gram-positive bacterial biofilms, Gram-negative bacterial biofilms, fungal biofilms and/or growth of micro-organisms such as fungi, protozoa, bacteria and/or
viruses. In various embodiments, applying the MBSFL oil 140 may be carried out in any of dermal, topical and/or oral applications (see examples below); for disinfecting medical equipment such as catheters; and/or in industrial applications such as disinfecting pipes.
[0030] Certain embodiments comprise compositions or formulations comprising MBSFL oil, modified from BSFL oil extracted from processed BSFL and comprising monoglycerides, fatty acid salts and/or FFA of MCFAs converted from triglycerides in the BSFL oil. In certain embodiments, the compositions or formulations may comprise topical dermal and/or oral formulations. In certain embodiments, the compositions or formulations may comprise compositions for disinfecting medical equipment such as catheters and/or industrial pipework.
[0031] Figure 2 is a high-level schematic illustration of a system 200, according to some embodiments of the invention. System 200 comprises an extraction unit 210 configured to extract BSFL oil 215 from BSFL 90, a conversion unit 220 configured to convert triglycerides in prepared BSFL oil 215 into monoglycerides, fatty acid salts and/or FFA of MCFAs - to yield modified black soldier fly larvae (MBSFL) oil 225, and a formulation unit 240 configured to prepare from MBSFL oil 225 a formulation 245 that suppresses biofilm development and/or microorganism growth 260, e.g., of bacteria, fungi, viruses and/or protozoa. It is noted that the MCFAs may comprise mainly lauric acid, for example in the form of laurate, e.g., sodium laurate, potassium laurate etc., monolaurin and/or free lauric acid.
[0032] In an experimental, non-limiting example, BSFL 90 were used as raw material, after drying to a moisture content of less than 3%, to extract oil therefrom using a mechanical press (expeller). In certain embodiments, solvent extraction (e.g., using hexane, petroleum ether, water) or other technologies may be applied to process BSFL 90. MBSFL oil 225 (converted from BSFL oil 215), was prepared using a saponification process (by which triglycerides are reacted with sodium or potassium hydroxide to produce glycerol and a fatty acid salt). BSFL oil 215 was heated to 60-70°C. KOH was mixed with bi-distilled water at a 1 :3 ratio accordingly, and then mixed with heated BSFL oil 215 in a ratio according to its saponification number, which was set to 19.9% (2500g BSFL oil, 1500g bi-distilled H20, 497.5g KOH analytical). In another example, a similar mixture was prepared, but with an excess amount of KOH (5% more than indicated according to the saponification number). In the data below resulting MBSFL oil 225 (indicated as lot 0030.111217-181125) compared to the source BSFL oil 215 (indicated as lot 0030.111217). Once a homogenous blend was reached, it was then mixed with an electric hand mixer for 20 seconds every one minute, until a viscous mixture was
obtained. The mixture was then transferred to a double jacket heated pot, and was heated followed by a gentle mixing every 20 minutes. The end of the heating process was set to 15% decrease in water content (which took approximately three hours).
[0033] Table 1 provides results of triacylglycerols (TAG), diacylglycerols (DAG) and monoacylglycerols (MAG) composition, and Free Fatty Acids (FFA) for BSFL oil and converted, MBSFL oil. BSFL oil glycerides composition contains mainly TAG, with no DAG or MAG detected. The saponification process increased MAG composition in the sample to 7.3 (g/lOOg Oil), dominated by the dodecanoic (lauric) acid monoglyceride (2.39 g/lOOg Oil).
Table 1: TAG, DAG and MAG composition and FFA content in BSFL oil before and after conversion (test method for DAG, MAG composition: MP 0118 REV3 2012; Test method for TAG composition: REG CE 273/2008; Test method for FFA: AOCS Ca 5a-40).
[0034] Table 2 provides data of the fatty acids profile of the MBSFL oil. Laurie acid, 02:0, is the major component of medium-chain fatty acids (MCFAs) found in the MBSFL oil (45.48 g/lOOg oil), however, MBSFL oil contains additional MCFA capric acid, 00:0 (1.03g/100g oil). MBSFL oil contains additional fatty acids such as n-6 linoleic acid, 08:2 (10.7603g/100g oil), n-7 palmitoleic acid, 06:1 (3.09g/100g oil) and n-9 oleic acid, 08:1 (12.5303g/100g oil). These fatty acids were found to exert significant antimicrobial activity against various microorganisms such as oral pathogens Streptococcus mutans, Candida albicans, Aggregatibacter actinomycetemcomitans , Fusobacterium nucleatum, and Porphyromonas gingivalis (Fluang 2010, Antimicrobial activity of n- 6, n-7 and n-9 fatty acids and their esters for oral microorganisms, Arch Oral Biol, 55(8): 555-560; Dilika et al. 2000, Antibacterial activity of linoleic and oleic acids isolated from Helichrysum pedunculatum: a plant used during circumcision rites; Fitoterapia, 71(4): 450-452). MBSFL oil contains 0.77g/100g oil n-3 alpha linolenic acid (Cl 8:3). In a study it was demonstrated that alpha linolenic acid and its ester derivatives exhibited strong antibacterial activity against various oral pathogens, including S. mutans, C. albicans, A. actinomycetemcomitans, F. nucleatum, and P. gingivalis (Huang et al. 2010, A novel bioactivity of omega-3 polyunsaturated fatty acids and their ester derivatives; Molecular Oral Biology 25(l):75-80). MBSFL oil contains also 10.19g/100g oil myristic acid (Cl 4:0) which was shown to inhibit the growth of the Gram positive bacterium, L. monocytogenes (Chen et al. 2019; Antimicrobial potential of myristic acid against Listeria monocytogenes in milk; The Journal of Antibiotics 72:298-305). Therefore, it is possible that the combination of MCFAs lauric acid (02:0) and capric acid (00:0) with potential antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06: 1), oleic acid (08:1), linoleic acid (08:2) and/or
alpha linolenic acid (C18:3) also composing the MBSFL oil and undergo the conversion process (saponification) contributes to the overall antimicrobial and antibiofilm properties of the MBSFL oil.
Table 2: Fatty acid profile of BSFL oil before and after conversion (MBSFL oil). Test methods: EN 12966-2, EN 12966-1 and EN 12966-4.
[0035] In certain embodiments, MBSFL oil 225 may comprise a combination of MCFAs lauric acid (02:0) and capric acid (00:0) with optional antimicrobial fatty acids myristic acid (04:0), palmitoleic acid (06:1), oleic acid (08:1), linoleic acid (08:2) and/or alpha linolenic acid (08:3), converted by saponification and/or hydrolysis from the respective fatty acid triglycerides - to yield antimicrobial and antibiofilm properties.
[0036] It is noted that in certain embodiments, extraction unit 210 and conversion unit 220 may be operated in reversed order, or possibly in parallel, so that the triglycerides are converted into monoglycerides, fatty acid salts and/or FFA of MCFAs already in BSF larvae 90 and prior to separation of (MCFAs-rich) BSFL oil as MBSFL oil 225.
[0037] In certain embodiments, conversion unit 220 may be configured to convert the triglycerides into monoglycerides, fatty acid salts and/or FFA of MCFAs by saponification and/or hydrolysis (e.g., acidic or enzymatic). Conversion unit 220 may be configured to break off fatty acids from triglyceride fats in BSFL oil 215 to form monoglycerides and/or free fatty acids and/or fatty acid salts that exert the antimicrobial activity.
[0038] For example, in certain embodiments, BSFL 90 may be grinded and blanched and/or heated, the pH of the resulting slurry may be adjusted, and the slurry may then be subjected to lipolytic enzymes such as lipase, to increase free lauric acid fractions (releasing lauric acid from the triglyceride complex). The slurry may then be heated to inactivate the enzymes and the slurry may be separated into its oil, protein and water fractions, e.g., using a decanter and/or a centrifuge. Alternatively, or complementarily, the lipase enzymes may be added after the separation stage, to the oil fraction and/or to the meal fraction separately. Alternatively, or complementarily, the slurry may be dried to produce whole fat insect meal with modified oil having increased antimicrobial properties. In certain embodiments, the remaining meal fraction may have high oil content (e.g., 10% or more) and may be further treated to yield additional laurate, monolaurin and/or free lauric acid-enriched products. In certain embodiments, lipolytic enzymes may be used to decompose the lipids, e.g., as taught by Japanese Patent Publication No. 2009254348 for processing bee larvae.
[0039] MBSFL oil 225 may be rich in monolaurin and free lauric acid and/or laurate, and as a result have antimicrobial properties for a wide range of applications, without requiring the digestion of BSFL oil with triglycerides by animals that is taught in the prior art.
[0040] In certain embodiments, system 200 may further comprise a separation unit 230 configured to separate MCFAs 235 from MBSFL oil 225 and optionally enrich MBSFL oil 225 with extracted MCFAs 235. For example, Nomlaini et al. describes the separation of lauric acid and oleic acid in palm kernel oil using fractional supercritical carbon dioxide (SC-CO2) extraction (Nomlaini et al. 2004, Supercritical enhancement for separation of lauric acid and oleic acid in palm kernel oil (PKO); Separation and Purification Technology 39, 133-138). Alternatively, the glycerol fraction can be extracted out, leaving behind MCFAs rich fraction together with additional essential fatty acids. An example for purifying glycerol is described by H.W. Tan et al., using a distillation process (Tan et al. 2013, Glycerol production and its applications as a raw material: A review; Renewable and Sustainable Energy Reviews 27, 118-127). In certain embodiments, separation unit 230 may be configured to separate out glycerol from the MBSFL oil to yield MCFAs-rich MBSFL oil.
[0041] In certain embodiments, formulation 245 may be configured to suppress any of Gram positive bacterial biofilms, Gram-negative bacterial biofilms, fungal biofilms and/or growth of microorganisms. In certain embodiments, formulation 245 may be configured to be applicable in at least one of: Dermal applications, topical therapy, oral applications, medical equipment and/or industrial applications (see examples below). In certain embodiments, formulation 245 may be configured to prepare the formulation as a dermal or oral creme, semm, wash, suspension and/or solution, or any other type of formulation. In certain embodiments, system 200 may further comprise an applicator 250, such as any appropriate device like a dispenser, collapsible container, sprayer etc., configured to apply formulation 245.
[0042] In certain embodiments, the conversion process may be configured to enhance BSFL oil dissolution in water, resulting in MBSFL oil with improved solubility with respect to BSFL oil. For example, low water solubility of a substance may sometimes be used to modify its relative antimicrobial inactivity (Griffin et al., 1999, The role of structure and molecular properties of terpenoids in determining their antimicrobial activity; Flavour and Fragrance Journal 14(5): 322-332). In addition, solubility could well be a limiting factor with respect to practical applications. Table 3 provides solubility data for BSFL oil before and after the saponification (conversion) process.
Table 3: Solubility data of BSFL oil, before and after conversion to MBSFL oil. Test method: Food Chemicals Codex (FCC).
[0043] The following data demonstrate, in a non-limiting manner, the application of the MBSFL oil to suppress biofilm development and/or microorganism growth. MBSFL oil (converted, 225, BioBee Sde Eliyahu Ltd, lot 0095-0098.181210-181227) was compared to BSFL oil (before conversion, 215, BioBee Sde Eliyahu Ltd, lot 0030.111217), lauric acid 98% (Sigma-Aldrich, denoted LA) and chlorhexidine acetate (Steinberg, denoted CHX), were analyzed as antimicrobial and anti-biofilm- formation agents in vitro, with respect to Pseudomonas aeruginosa (Gram negative, denoted PA01),
Staphylococcus aureus (ATCC, American Type Culture Collection) (Gram positive, denoted SA), Streptococcus mutans (ATCC) (Gram positive, denoted SM), Lactobacillus (ATCC) (Gram positive, denoted L), Candida albicans (ATCC) (yeast, denoted CA) and Candida glabrata (ATCC) (yeast, denoted CG).
[0044] Microbial stocks of the Biofilm Research Laboratory were grown from frozen stock: SM at overnight 37°C in BHI (brain heart infusion) broth medium in an atmosphere of 5% CO2; L at 37°C in MRS (de Man, Rogosa and Sharpe) broth medium in an atmosphere of 5% CO2; PAOl and SA at 37°C in TSB (Trypticase soy broth) medium; CA and CG at 37°C in RPMI (Roswell Park Memorial Institute) medium.
[0045] BSFL oil and MBSFL oil were prepared in DDW by heating at 100°C. LA was prepared at 50% Ethanol / 50% DDW (doubly distillated water) and heated constantly to prevent solidifying in the tube. Maximum concentration of tested agents was the same (2.7% of lauric acid content). CHX was prepared in DDW
[0046] To examine the effects of MBSFL oil on microorganism's growth (planktonic conditions), serial 1 :2 dilutions of each tested agent in appropriate medium (BSFL, MBSFL and LA from 2.7 to 0.04%; CHX from 20 pg/ml to 0.3 pg/ml) were prepared in a polystyrene flat-bottomed 96-well microplate. Wells with no compounds and those with bacteria served as positive controls. Wells with no bacteria and with compound served as blanks. An equal volume (100 mΐ) of the each tested bacterial and fungal suspension at optical density (OD)595=0.02 and 0.05, respectively, was added to each well. After a 24 h incubation, growth was monitored by recording the OD at 595 nm using a Genius plate reader Spectrophotometer (Tecan). The assay was performed in triplicates.
[0047] To examine the effects of MBSFL oil on microorganism’s viability, equal amounts (5pl) of bacterial suspension exposed to each tested concentration of agent was plated on agar plates. Plates were incubated overnight at 37°C. Colony growth was recorded as non-affected by agent's viable bacteria. Minimal Bactericidal Concentration (MBC) was recorded as no colony growth. Minimal Fungicidal Concentration (MFC) was recorded as no fungal growth.
[0048] To examine the effects of MBSFL oil on biofilm formation by the microorganisms, assays for all of the tested agents were performed as described above except of growth medium used which was MRS/BHI supplemented with 1% sucrose and TSB / RPMI supplemented with 1% glucose. After incubation for 24 h, spent media and free-floating bacteria/fungi were removed by gentle aspiration and the wells were washed twice with phosphate -buffered saline (PBS, pH 7.4). The biofilm was then
quantified by crystal violet staining. Briefly, 0.02% crystal violet was added into wells for 45 min, which were then washed twice with DDW to remove unbound dye. After adding 200 mΐ of 30% acetic acid into each well, the plate was shaken for 10 min to release the dye and the biofilm was quantified by measuring the absorbance at 595 nm using a Genius plate reader Spectrophotometer (Tecan). Assay was performed in triplicates.
[0049] Figure 3 provides results of the effect of BSFL oil on Pseudomonas aeruginosa (PAOl) growth in planktonic environment, according to some embodiments of the invention. The means and standard deviations of the bacterial growth are shown, and significant differences (from no BSFL oil, p<0.01) according to Student’s t-test are denoted be asterisks (*). No minimum inhibitory concentration (MIC) was detected, however, PAOl growth was reduced dose-dependently with increasing BSFL oil doses. BSFL oil at doses of 0.28%, 0.56%, 1.12% and 2.25% was able to decrease PAOl growth by 23%, 37%, 55% and 60%, respectively.
[0050] Figures 4A-F provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on the growth of various types of microorganisms in planktonic environment, specifically Pseudomonas aeruginosa (PAOl, Figure 4A), Staphylococcus aureus (SA, Figure 4B), Streptococcus mutans (SM, Figure 4C), Lactobacillus (L, Figure 4D), Candida albicans (CA, Figure 4E) and Candida glabrata (CG, Figure 4F), according to some embodiments of the invention. The effect of BSFL oil on microorganism's growth was compared to MBSFL oil and lauric acid 98%. The effect of BSFL oil was at a much lower degree in comparison with MBSFL oil, as MBSFL oil was able at dose of 1.35% to reduce more than 80 % of PAOl growth (Figure 4A). Among all tested microbes, planktonic growth was notably affected by BSFL oil in regard to PAOl only. As the effect of BSFL oil on the rest of the microorganisms tested was negligible, data are not shown. It is noted that in the presented experiments, gram-positive bacterial and fungal growth were inhibited by MBSFL oil and not by native BSFL oil. Figure 4B, 4C, 4D, 4E and 4F illustrate the effect of MBSFL oil in comparison with LA on planktonic growth for SA, SM, L, CA and CG, respectively. Both MBSFL oil and LA dramatically affected growth of SA: LA already at lowest tested dose of 0.04 % reduced SA growth by 90%, while MBSFL in range of doses 0.04 %-0.67 % reduced bacterial growth by 75%, exhibiting MIC at dose of 1.35% (Figure 4B). MBSFL oil moderately reduced SM growth, however it did not exhibit either MIC or MBC. In contrast, LA notably decreased bacterial growth and was able to exhibit MIC at dose of 0.33% (Figure 4C). Both MBSFL oil and LA dramatically affected L growth: MICs for LA and MBSFL were 0.33% and less than 0.04%, respectively (Figure
4D). Both MBSFL and LA notably reduced fungal growth: MBSFL oil demonstrated inhibition of CA growth, with MIC at dose of 0.33%. LA was less potential than MBSFL oil by exhibiting MIC at dose of f .35% (Figure 4E). For CG, MBSFL oil demonstrated moderate inhibition of CG growth, with non-detectable MIC. LA was more potential by exhibiting MIC at dose of 2.7% (Figure 4F). These data altogether, indicate that conversion 120 significantly increased the anti-microbial effects of the BSFL oil.
[0051] Although MBSFL oil results show growth inhibition effect, no MBC/MFC was detected for MBSFL oil at all tested doses for all of the microorganisms tested: PAOl, SA, SM, CA and CG. Only exception is with L, for which MBC for MBSFL oil was less than 0.08%. Whereas MBC/ MFC for MBSFL oil was detected for one microbe only, LA exerted MBC/ MFC for all tested microbes, except PAOl : MBC for SA was detected at dose of 0.67%, MBC for SM was detected at dose of 0.33%, MBC for L was detected at dose of 0.67%, MFC for both CA and CG was detected at dose of 2.7%.
[0052] Figure 5 provides comparative results indicating the effect of BSFL oil on biofilm formation of Staphylococcus aureus (SA), according to some embodiments of the invention. Unmodified BSFL oil caused insignificant effect on biofilm formation, affecting only SA by a moderate decrease of biofilm formation in the range of 20%-29%. As biofilm formation of the rest of microbes was not affected by BSFL oil, data are not shown.
[0053] Figures 6A-E provide comparative results indicating the effect of MBSFL oil and lauric acid (LA) on biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 6A), Staphylococcus aureus (SA, Figure 6B), Streptococcus mutans (SM, Figure 6C), Candida albicans (CA, Figure 6D) and Candida glabrata (CG, Figure 6E), according to some embodiments of the invention. Figures 6A-6E illustrate that the modification of BSFL oil increased its antibiofilm properties. In addition, MBSFL oil demonstrated a much more pronounced effect on biofilm formation of all tested microbes as compared to LA: MBSFL oil at doses of up to 0.33% increased biomass of PAOl, while increasing MBSFL oil doses starting from 0.67% inhibition of biofilm formation. MBSFL oil at doses of 1.35% and 2.7 % almost totally inhibited biofilm formation. In contrast, LA dose-dependently increased biomass at all concentrations tested (Figure 6A). Biofilm formation of SA was dramatically inhibited by MBSFL oil already at lowest tested dose of 0.04% (almost no biofilm was formed), while LA was able dose-dependently to decrease biofilm formation and at 0.67% was totally inhibited biofilm formation (Figure 6B). MBSFL oil and LA also exerted obvious anti-biofilm effect against SM: LA was able to totally inhibit biofilm formation at dose of
0.16%, while MBSFL oil was even more effective demonstrating total biofilm inhibition at dose lower than the lowest tested dose (Figure 6C). Biofilm formation of CA was strongly affected by both MBSFL oil and LA, with a stronger inhibition effect of MBSFL oil compared to LA: MBSFL oil was able almost totally to inhibit biofilm formation of CA at dose of 0.08%, in comparison with dose of 0.67% for LA (Figure 6D). Biofilm formation of CG was inhibited by MBSFL oil by 80% already at lowest tested dose of 0.04%. LA was also effective against biofilm formation of CG but with less impact (Figure 6E). Since biofilm of L was very weak and easily washed out, no data were demonstrated on biofilm formation.
[0054] Figures 7A-F provide comparative results indicating the effect of chlorhexidine acetate (CHX) on planktonic growth and biofilm formation of various types of microorganisms: Pseudomonas aeruginosa (PAOl, Figure 7A), Staphylococcus aureus (SA, Figure 7B), Streptococcus mutans (SM, Figure 7C), Lactobacillus (L, Figure 7D), Candida albicans (CA, Figure 7E) and Candida glabrata (CG, Figure 7F), according to some embodiments of the invention. The positive control agent, CHX, exhibited total inhibition of P AO 1 growth and biofilm formation at the same dose of 10 pg/ml (Figure 7A), MBC was detected at dose of 20 pg/ml. CHX inhibited growth and biofilm formation of SA at the same dose of 2.5 pg/ml (Figure 7B), MBC was detected at dose of 10 pg/ml. CHX inhibited growth, biofilm formation and exhibited MBC against SM at the same dose of 0.625 pg/ml (Figure 7C). MIC and MBC for CHX against L were detected at the same dose of 2.5 pg/ml (Figure 7D). Since biofilm of L was very weak and easily washed out, no data were demonstrated on biofilm formation. CHX inhibited growth and biofilm formation of CA and CG and exhibited MFC at the same dose of 5 pg/ml and 2.5 pg/ml (Figures 7E and 7F, respectively). CHX serves as a positive control, demonstrating a non-specific killing effect.
[0055] The following data demonstrate, in a non-limiting manner, the antifungal activity of MBSFL oil against the following fungi: Trichophyton rubrum (denoted T. rubrum ), Microsporum canis (denoted M. canis ) and Epidermophyton floccosum (denoted E. floccosum). MBSFL oil (converted, 225, BioBee Sde Eliyahu Ltd, lot 0095-0098.181210-181227) was tested in vitro in comparison with the antifungal dmgs Bifonazole and Terbinafine.
[0056] MBSFL oil was prepared in DDW at a 1 :1 ratio by heating and stirring at 100°C. Bifonazole and Terbinafine were used as is.
[0057] Fungi strains (SB Clinic research center, mycological laboratory, Israel) were taken and inoculated in Sabouraud dextrose agar broth at 33±1 °C.
[0058] To examine the effect of MBSFL oil on fungi growth, Sabouraud Dextrose Agar (SDA) was heated to liquification and then each reagent was suspended in SDA grown medium in the following ratio: 13% MBSFL oil (Group B), 13% Bifonazole (group C) and 20% Terbinafine (group D). Group A of plates with SDA agar grown medium with no reagent addition served as control. Finally, the grown medium of each group was poured to agar plates (2 ml plate), and allowed to dry. When the petri dishes had dried, 1.5X1.5cm of each fungus was placed in the center of each petri dish. Plates were incubated at 35±2°C for 22 days. The plates were then taken out after 7, 14, 18 and 22 days and on each day the fungi diameter was measured using a scale.
[0059] Tables 4A and 4B provide experimental results indicating the antifungal efficiency of MBSFL oil, according to some embodiments of the invention. Table 4A provides comparative results indicating the effect of MBSFL oil, Bifonazole and Terbinafine on the growth of T. rubrum, M. canis and E. floccosum. MBSFL oil exhibited full growth inhibition against all fungi tested, similar to Bifonazole and Terbinafine at the specific concentration tested. Table 4B provides experimental results comparing MBSFL oil to Terbinafine hydrochloride 1% % w/w in spray topical formulation (Lamisil®) in their efficiency to inhibit Trichophyton rubrum growth. Fungal growth was monitored over two weeks in petri dishes containing dissolved SDA (Sabouraud Dextrose Agar) substrate with T. rubrum samples.
Table 4A: The effect of antifungal agents against T. rubrum, M. canis and E. floccosum growth vs. time.
Table 4B: Experimental results comparing MBSFL oil to Terbinafine hydrochloride 1% (Lamisil®) asinhibitors of T. rubrum growth.
[0060] The results indicate that MBSFL oil at 4% concentration inhibits T. rubrum growth in vitro as good as the known antifungal agent Lamisil®, indicating it being a potent anti-fungal agent. The anti-fungal activity of MBSFL oil in this experiments was dose dependent, with low concentrations (1%) not being active. As Lamisil® is used to treat tinea pedis (athlete's foot) and tinea cmris (dhobie itch/jock itch) caused by Trichophyton (e.g., T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum ) and Epidermophyton floccosum, there are good grounds to suggest that MBSFL oil is likewise efficient in treating tinea pedis and related fungal infections in dermatological and non- dermatological diseases.
[0061] It is noted that the concentration of the MBSFL oil for inhibiting growth of micro-organisms is not limited to the values shown in the experiments above. Specifically, the required MBSFL oil concentrations depend on the composition of specific types of MBSFL oil, on the type(s) of micro-
organism(s) of which growth is to be inhibited and on the conditions of the application. For example, the MBSFL oil was shown in preliminary experiments to inhibit growth of Candida albicans at a concentration of about 0.3%. Accordingly, the concentration of the MBSFL oil may be any of at least 0.1%, 0.3%, 0.5%, 1%, 2%, 3%, 5%, 10% or any intermediate value or range of values.
[0062] In certain embodiments, MBSFL oil may be used to inhibit viral growth, as disclosed above. For example, vimses such as Porcine Epidemic Diarrhea Virus (PEDV), fat-enveloped viruses (e.g., Marek, Newcastle disease (ND), infectious bronchitis (IB), avian influenza (AI)), Vesicular stomatitis virus (VSV) strain Indiana, Herpes simplex virus type 1 (HSV-1) strain MacIntyre, Visna Virus (VV), Junin vims (JUNV), HIV vims and possibly Covid 19/ nCoV-2019 were shown to be inhibited by lauric acid, monolaurin, medium-chain fatty acids (MCFA) and/or coconut oil, indicating the potential anti-viral efficiency of disclosed MBSFL oil.
[0063] It is suggested, without being bound by theory, that antiviral fatty acids (and especially their monoglycerides) may cause leakage of the viral envelope, and at higher concentrations, may cause a complete disintegration of the envelope and of the viral particles, and possibly also disintegration of the plasma membranes of tissue culture cells resulting in cell lysis and death. The fatty acid concentration required for maximum viral inactivation may vary and can be determined experimentally, with respect to the type of MBSFL oil and details of the application.
[0064] To summarize, the data show that the modification of the BSFL oil by converting triglycerides to monoglycerides, fatty acid salts and/or free fatty acids (FFA) of lauric acid notably enhances its antimicrobial properties, both in planktonic and biofilm environment. In addition, the MBSFL oil's effect on bacterial and fungal growth was similar to that of LA. However, MBSFL oil demonstrated a much more profound effect on biofilm formation for all tested microbes as compared to LA. Moreover, MBC /MFC for MBSFL oil was detected for one microbe only. In contrast, LA exerted MBC/ MFC for all tested microbes, except PAOl. Antibacterial agents are usually regarded as bactericidal if the MBC is no more than four times the MIC. Due to its strong inhibitory effect on biofilm formation with no bactericidal effect, which may reflect a unique and specific activity, MBSFL oil may be used as a specific anti-biofilm compound that is unique and applicable in many clinical applications and may be applied to additional pathogens and possibly in a sustained release delivery system.
[0065] Non-limiting examples for possible applications of converted BSFL meal or oil, and/or lauric acid derived therefrom and/or formulations containing either preparations comprise a range of
antibacterial, anti-viral and anti-fungal uses, against planktonic microorganisms and/or as anti-biofilm agents. For example, dentistry applications may comprise oral cavity applications such as treatment of thrush, stomatitis and orthodontal issues or presentation of caries and plaque induced gingivitis or periodontitis. For example, formulations 245 may comprise mouthwash, toothpaste, either as adjuvant or as stand-alone formulations. In additional examples, applications may comprise dermal applications such as: (i) Atopic dermatitis, psoriasis, contact dermatitis and/or diaper rash - BSFL/MBSFL oil may affect the dryness of the skin by its moisturizing properties and in addition, MBSFL oil may prevent the development of secondary infections, such as by S. aureus, which are known to develop in these diseases following patient scratching of the skin area, due to the itching symptom; (ii) Tinea pedis (fungal infection of legs) - BSFL/MBSFL oil may affect the fungal infection of the skin by its antifungal properties, and in addition, MBSFL oil may prevent the development of secondary bacterial infections, which are known to be developed in these diseases following patient scratching of the skin area, due to the itching symptom. Additional indications of the same family are scalp dandruff or seborrheic dermatitis, Pityriasis versicolor, cutaneous candidiasis, Tinea corporis and Tinea cruris. In various embodiments, formulation 245 may be used to treat (iii) Dermatophytosis - MBSFL oil may be useful against Trichophyton rubrum fungi (T. rubrum is a dermatophyte fungus responsible for a fungal infection of the skin known as dermatophytosis), and/or (iv) Onychomycosis (Tinea unguium, nail fungal infection) - MBSFL oil may be useful for this and other dermatology indications. In various embodiments, formulation 245 may be used to treat (v) acne vulgaris - In vitro studies (Nakatsuji et al. 2009, Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris, J Invest Dermatology 129(10): 2480-2488) indicate antimicrobial properties of lauric acid against Propionibacterium acnes and highlight the potential of using lauric acid as an alternative treatment for antibiotic therapy of acne vulgaris. In various embodiments, formulation 245 may be used to treat (vi) urinal tract infections. In various embodiments, formulation 245 may be used to treat (vii) vaginal infections - MBSFL oil may be useful for treating Candida (as was indicated for both Candida albicans and Candida glabrata ) and bacterial vaginosis due to its antibacterial and antifungal effects, e.g., for treatment of vaginal dryness and for avoiding irritation, e.g., with formulation 245 used as intimal wash and/or vaginal capsules. In various embodiments, formulation 245 may be used to treat (viii) ear infection (otitis externa, acute otitis media) and/or (ix) Xerosis and/or providing anti aging effects on skin - MBSFL oil may be useful for providing moisturizing effects, inhibition of skin
water loss and enhancing of skin regeneration capability effects of lauric acid and linoleic acid. In various embodiments, formulation 245 may be used to treat (x) Diabetic foot ulcers (DFU), being one of the most severe complications in Diabetes mellitus. Ischemic and neuropathic lesions are of major importance for DFU onset; however, it is the infection by multidrug-resistant and biofilm-producing microorganisms, along with local microenvironmental conditions unfavorable to antibiotics action that ultimately cause infection chronicity and lower limbs amputation. MBSFL may be useful for treating DFU as it exerts a strong inhibitory effect on biofilm formation of both S. aureus and P. aeruginosa which are the predominant Gram-positive and Gram-negative species present in DFU, respectively (Santos et al. 2016, Guar gum as a new antimicrobial peptide delivery system against diabetic foot ulcers Staphylococcus aureus isolates, Journal of Medical Microbiology 65, 1092-1099). In various embodiments, formulation 245 may be used to treat (xi) Infections on the skin caused by antibiotic resistant bacteria. For example, MBSFL may be useful for treating Methicillin-resistant S. aureus (MRSA), a bacterium that causes infections in different parts of the body and is resistant to penicillin. In various embodiments, formulation 245 may be used to treat (xii) oral candidiasis (caused by Candida albicans accumulation). In various embodiments, formulation 245 may be used in (xiii) additional applications for local treatment with various types of viral infection related to Herpes: Herpes labialis, Herpes zoster and/or genital herpes. In various embodiments, formulation 245 may be used to treat (xiv) autoimmune diseases causing thickened skin such as Scleroderma and Ichthyosis. In various embodiments, formulation 245 may be used to treat (xv) various types of radiation burns, for example sunburn. Additional applications may comprise anti-biofilm coatings of catheters, implant devices, prostheses, mechanical valves, ventricular shunts, pacemakers, defibrillator, ventricular-assisted devices, Intervertebral disc and/or contact lenses to prevent device-associated infections of biofilm. Additional applications are industrial, such as anti-biofilm coatings on boats and/or pipes, cleaning agents for surfaces (e.g., tables) that remove bacterial infections (e.g., for hospitals, labs, kitchens, etc.). Additional examples for MBSFL oil applications may comprise veterinary applications as adjuvant in vaccines (fish, poultry) and topical applications in cats and dogs to promote the healing of cuts, wounds, hot spots, dry skin and hair, bites and stings, itching areas, as well as to prevent and treat yeast and fungal infections, including Candida and possibly to reduce or eliminate bad breath in dogs
[0066] In the above description, an embodiment is an example or implementation of the invention. The various appearances of "one embodiment”, "an embodiment", "certain embodiments" or "some
embodiments" do not necessarily all refer to the same embodiments. Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein in the context of separate embodiments for clarity, the invention may also be implemented in a single embodiment. Certain embodiments of the invention may include features from different embodiments disclosed above, and certain embodiments may incorporate elements from other embodiments disclosed above. The disclosure of elements of the invention in the context of a specific embodiment is not to be taken as limiting their use in the specific embodiment alone. Furthermore, it is to be understood that the invention can be carried out or practiced in various ways and that the invention can be implemented in certain embodiments other than the ones outlined in the description above.
[0067] The invention is not limited to those diagrams or to the corresponding descriptions. For example, flow need not move through each illustrated box or state, or in exactly the same order as illustrated and described. Meanings of technical and scientific terms used herein are to be commonly understood as by one of ordinary skill in the art to which the invention belongs, unless otherwise defined. While the invention has been described with respect to a limited number of embodiments, these should not be constmed as limitations on the scope of the invention, but rather as exemplifications of some of the preferred embodiments. Other possible variations, modifications, and applications are also within the scope of the invention. Accordingly, the scope of the invention should not be limited by what has thus far been described, but by the appended claims and their legal equivalents.
Claims
1. A method comprising:
extracting black soldier fly larvae (BSFL) oil by processing BSFL,
modifying the BSFL oil into modified BSFL (MBSFL) oil by converting triglycerides in the BSFL oil to monoglycerides, fatty acid salts and/or free fatty acids (FFA) of medium chain fatty acids (MCFAs), and
applying the MBSFL oil to suppress biofilm development and/or microorganism growth.
2. The method of claim 1, further comprising extracting the MCFAs from the MBSFL oil and applying the extracted MCFAs to suppress biofilm development and/or microorganism growth.
3. The method of claim 1, further comprising enriching the MBSFL oil with MCFAs.
4. The method of any one of claims 1-3, wherein the converting is carried out by saponification and/or hydrolysis.
5. The method of any one of claims 1 -4, wherein the converting is carried out to enhance a solubility of the converted MBSFL oil with respect to the BSFL oil.
6. The method of any one of claims 1-5, wherein the applying is carried out against at least one of:
Gram-positive bacterial biofilms, Gram-negative bacterial biofilm, fungal biofilm and growth of microorganisms .
7. The method of any one of claims 1-5, wherein the applying is carried out in at least one of: a dermal application and an oral application.
8. The method of any one of claims 1 -5 , wherein the applying is carried out on at least one of: Atopic dermatitis, psoriasis, contact dermatitis, diaper rash, Tinea pedis, Dermatophytosis, Onychomycosis, Acne vulgaris, urinal tract infections, vaginal infections, ear infection, Xerosis, aging effects on the skin, diabetic foot ulcers, infections on the skin caused by antibiotic resistant bacteria, oral candidiasis, viral infection related to Herpes, autoimmune diseases, radiation bums, and topical therapy.
9. The method of any one of claims 1-5, wherein the applying is carried out on at least one of: medical equipment and catheters.
10. The method of any one of claims 1-5, wherein the applying is carried out in at least one of: an industrial application, pipes and ship’s ballast water pipework.
11. The method of any one of claims 1-5, wherein the applying is carried out in veterinary applications comprising at least one of: vaccine adjuvant for fish and/or poultry, topical applications in cats and dogs to promote the healing of cuts, wounds, hot spots, dry skin and hair, bites and stings, itching areas, as well as to prevent and treat yeast and fungal infections, including Candida and/or to reduce or eliminate bad breath in dogs.
12. The method of any one of claims 1-11, wherein the MCFAs comprise lauric acid in the form of laurate, monolaurin and/or free lauric acid.
13. A topical dermal or oral composition, comprising modified black soldier fly larvae (MBSFL) oil, modified from BSFL oil extracted from processed BSF larvae and comprising monoglycerides and/or fatty acid salts and/or free fatty acids of medium chain fatty acids (MCFAs) converted from triglycerides in the BSFL oil.
14. The topical dermal or oral composition of claim 13, wherein the MCFAs comprise lauric acid in the form of laurate monolaurin and/or free lauric acid.
15. A system comprising:
an extraction unit configured to extract black soldier fly larvae (BSFL) oil from BSFL, a conversion unit configured to convert triglycerides in the prepared BSFL oil into monoglycerides, fatty acid salts and/or free fatty acids of medium chain fatty acids (MCFAs) - to yield modified BSFL (MBSFL) oil, and
a formulation unit configured to prepare from the MBSFL oil a formulation that suppresses biofilm development and/or microorganism growth.
16. The system of claim 15, wherein the conversion unit is configured to convert the triglycerides into the monoglycerides and/or fatty acid salts and/or free fatty acids of MCFAs by saponification and/or hydrolysis.
17. The system of claim 15, wherein the conversion unit is configured to enhance a solubility of the converted MBSFL oil with respect to the BSFL oil.
18. The system of any one of claims 15-17, further comprising a separation unit configured to extract the MCFAs from the MBSFL oil and enrich the MBSFL oil with the extracted MCFAs.
19. The system of any one of claims 15-17, further comprising a separation unit configured to separate out glycerol from the MBSFL oil to yield MCFAs-rich MBSFL oil.
20. The system of any one of claims 15-19, wherein the formulation is configured to suppress any of: Gram-positive bacterial biofilms and/or bacterial growth, Gram-negative bacterial biofilms and/or bacterial growth, fungal biofilms, fungal growth and/or growth of micro-organisms.
21. The system of any one of claims 15-20, wherein the formulation unit is configured to prepare the formulation as a dermal or oral creme, semm, wash, suspension and/or solution.
22. The system of any one of claims 15-20, wherein the formulation is configured to be applicable in at least one of: dermal applications, oral applications, topical therapy, medical equipment, catheters, industrial applications
23. The system of any one of claims 15-22, wherein the MCFAs comprise lauric acid in the form of laurate, monolaurin and/or free lauric acid.
24. The system of claim 23, wherein the MCFAs further comprises at least one of: capric acid (C10:0) in the form of capric acid salt (decanoate), monocaprin and/or free capric acid.
25. The system of claim 24, wherein the MBSFL oil comprises a combination of MCFAs lauric acid (C12:0) and capric acid (C10:0) with optional antimicrobial fatty acids myristic acid (C14:0), palmitoleic acid (C16:l), oleic acid (C18:l), linoleic acid (C18:2) and/or alpha linolenic acid (C 18:3), converted by saponification and/or hydrolysis from the respective fatty acid triglycerides - to yield antimicrobial and antibiofilm properties.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/613,522 US20220304916A1 (en) | 2019-05-23 | 2020-05-21 | Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth |
EP20809582.8A EP3972560A4 (en) | 2019-05-23 | 2020-05-21 | Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth |
IL288290A IL288290A (en) | 2019-05-23 | 2021-11-22 | Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962851942P | 2019-05-23 | 2019-05-23 | |
US62/851,942 | 2019-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020234884A1 true WO2020234884A1 (en) | 2020-11-26 |
Family
ID=73458959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2020/050560 WO2020234884A1 (en) | 2019-05-23 | 2020-05-21 | Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220304916A1 (en) |
EP (1) | EP3972560A4 (en) |
IL (1) | IL288290A (en) |
WO (1) | WO2020234884A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2794958C2 (en) * | 2021-06-22 | 2023-04-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный университет генетики, биотехнологии и инженерии имени Н.И. Вавилова" | Wound-healing composition |
WO2023163587A1 (en) * | 2022-02-22 | 2023-08-31 | Protix B.V. | Insect-derived, enzyme-modified lipid composition |
US12063934B2 (en) | 2022-05-10 | 2024-08-20 | Chonex, Inc. | Black soldier fly (Hermetia illucens) larvae frass formulations, combinations and uses |
WO2024180553A1 (en) * | 2023-03-02 | 2024-09-06 | Freezem Cryogenics Ltd. | High-weight black soldier fly larvae, methods of producing same and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067028A1 (en) * | 2005-12-07 | 2007-06-14 | Malaysian Agricultural Research And Development Institute (Mardi) | Modified coconut oils with broad antimicrobial spectrum |
WO2008090440A1 (en) | 2007-01-22 | 2008-07-31 | Carlo Ghisalberti | Lipid-based gynaecologic suppository |
US20180256483A1 (en) | 2015-11-16 | 2018-09-13 | Chanarong Sangduan | Skincare product containing hermetia illucens extract |
-
2020
- 2020-05-21 EP EP20809582.8A patent/EP3972560A4/en active Pending
- 2020-05-21 WO PCT/IL2020/050560 patent/WO2020234884A1/en unknown
- 2020-05-21 US US17/613,522 patent/US20220304916A1/en active Pending
-
2021
- 2021-11-22 IL IL288290A patent/IL288290A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067028A1 (en) * | 2005-12-07 | 2007-06-14 | Malaysian Agricultural Research And Development Institute (Mardi) | Modified coconut oils with broad antimicrobial spectrum |
US20100016430A1 (en) | 2005-12-07 | 2010-01-21 | Malaysian Agriculteral Research And Development In | Modified coconut oils with broad antimicrobial spectrum |
WO2008090440A1 (en) | 2007-01-22 | 2008-07-31 | Carlo Ghisalberti | Lipid-based gynaecologic suppository |
US20180256483A1 (en) | 2015-11-16 | 2018-09-13 | Chanarong Sangduan | Skincare product containing hermetia illucens extract |
Non-Patent Citations (13)
Title |
---|
ARIANE MULLER ET AL., ZEITSCHRIFT FUER NATURFORSCHUNG. C., vol. 72, no. 9-10, 25 July 2017 (2017-07-25), pages 351 - 363 |
CALIGIANI AUGUSTA ET AL., FOOD RESEARCH INTERNATIONAL, vol. 116, 13 August 2018 (2018-08-13), pages 276 - 282 |
GASCO ET AL.: "Can diets containing insects promote animal health?", JOURNAL OF INSECTS AS FOOD AND FEED, vol. 4, no. 1, 2018, pages 1 - 4 |
HESS ET AL.: "The natural surfactant glycerol monolaurate significantly reduces development of Staphylococcus aureus and En terococcusfaecalis biofilms", SURGICAL INFECTIONS, vol. 16, no. 5, 2015, pages 538 - 542 |
HORNUNG ET AL.: "Lauric acid inhibits the maturation ofvesicular stomatitis virus", JOURNAL OF GENERAL VIROLOGY, vol. 75, no. 2, 1994, pages 353 - 61 |
KUMAR PRASUN ET AL., TRENDS IN MICROBIOLOGY, vol. 28, no. 9, 28 April 2020 (2020-04-28), pages 753 - 768 |
LI SENLIN ET AL., AQUACULTURE, vol. 465, 18 August 2016 (2016-08-18), pages 43 - 52 |
LILAND ET AL.: "Modulation of nutrient composition of black soldier fly (Hermet in illucens) larvae by feeding seaweed-enriched media", PLOS ONE, vol. 12, no. 8, 2017, pages 0183188 |
PROJAN ET AL.: "Glycerol monolaurate inhibits the production of Blactamase, toxic shock syndrome toxin-1, and other staphylococcal exoproteins by interfering with signal transduction", J BACTERIOLOGY, vol. 176, 1994, pages 4204 - 4209, XP000564054 |
See also references of EP3972560A4 |
SHILLING ET AL.: "Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on Clostridium difficile", JOURNAL OF MEDICINAL FOOD, vol. 16, no. 12, 2013, pages 1079 - 1085, XP055598345, DOI: 10.1089/jmf.2012.0303 |
SHILLING, MICHAEL ET AL.: "Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on Clostridium difficile", JOURNAL OF MEDICINAL FOOD, vol. 16, no. 12, 30 July 2013 (2013-07-30), pages 1079 - 1085, XP055598345, DOI: 10.1089/jmf.2012.0303 * |
WITCHER ET AL.: "Modulation of immune cell proliferation by glycerol monolaurate", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 3, 1996, pages 10 - 13 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2794958C2 (en) * | 2021-06-22 | 2023-04-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный университет генетики, биотехнологии и инженерии имени Н.И. Вавилова" | Wound-healing composition |
WO2023163587A1 (en) * | 2022-02-22 | 2023-08-31 | Protix B.V. | Insect-derived, enzyme-modified lipid composition |
US12063934B2 (en) | 2022-05-10 | 2024-08-20 | Chonex, Inc. | Black soldier fly (Hermetia illucens) larvae frass formulations, combinations and uses |
WO2024180553A1 (en) * | 2023-03-02 | 2024-09-06 | Freezem Cryogenics Ltd. | High-weight black soldier fly larvae, methods of producing same and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3972560A4 (en) | 2023-08-09 |
EP3972560A1 (en) | 2022-03-30 |
US20220304916A1 (en) | 2022-09-29 |
IL288290A (en) | 2022-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5006886B2 (en) | Modified coconut oil with broad antibacterial spectrum | |
US20220304916A1 (en) | Modified black soldier fly larvae oil with modified lauric acid for treatment against biofilm formation and microorganism growth | |
AU2002324481B2 (en) | Emu-based formulations for wound treatment related application information | |
Silalahi et al. | Antibacterial activity of hydrolyzed virgin coconut oil | |
JP2011505415A (en) | Blends of free fatty acids and their use | |
AU2002324481A1 (en) | Emu-based formulations for wound treatment related application information | |
Kabara | Health oils from the tree of life | |
EP2922537B1 (en) | Antibacterial composition for topical use | |
US8835496B2 (en) | Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride for treating of skin, mucosa, hair, nails, or scalp | |
AU2014313866B2 (en) | Reaction platform and method for making pollen based materials in combination with beeswax and uses thereof | |
CA2809535C (en) | Antifungal composition | |
Harris et al. | The development and evaluation of melatonin-loaded, calcium oxide nanoparticle-based neem and clove extract: an in vitro study | |
EP2583662B1 (en) | Composition comprising a meroterpen to manage oily skin with tendency to develop acne | |
EP1883401B1 (en) | Anti-microbial agent | |
KR100454228B1 (en) | A feed additive for cultured fish | |
US20210393723A1 (en) | Composition for photodynamic reaction containing extract of ligularia fischeri as an effective ingredient, antimicrobial, antifungal and sterilization composition including the same, and sterilization method using the composition for photodynamic reaction | |
WO2022259727A1 (en) | Antibacterial composition production method, antibacterial composition, antibacterial method, antibacterial agent, cosmetic, and dermatological topical agent | |
Fransisca et al. | The effect of adding microalgae Spirulina platensis in making antibacterial soap | |
KR20240020468A (en) | A composition for inhibiting the formation of a biofilm of Staphylococcus aureus containing petrocelic acid as an active ingredient | |
CN113367168A (en) | Novel product applied to aquaculture animal disinfection and preparation method thereof | |
RU2138177C1 (en) | Method of preparing combined fodder premix for long storage | |
WO2017030836A1 (en) | Compositions and methods to treat infected ear conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20809582 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020809582 Country of ref document: EP Effective date: 20211223 |